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ABSTRACT 
 
Although there is ample evidence linking chronic inflammation with cancer, the 
cellular mechanisms involved in early events leading to tumor development remain 
unclear.  Myeloid cells are an intricate part of inflammation. They consist of mature cells 
represented by macrophages, dendritic cells and granulocytes and a population of 
Immature Myeloid Cells (IMC), which in healthy individuals are cells in transition to 
mature cells. There is a substantial expansion of IMC in cancer and many other 
pathological conditions which is associated with pathologic activation of these cells. As 
a result, these cells acquire the ability to suppress immune responses and are termed 
Myeloid-derived Suppressor Cells (MDSCs). Although the role of MDSC in immune 
suppression in cancer and tumor progression is well established, their contribution to 
tumor development is still uncertain. The fact that cells with MDSC phenotype and 
function are observed in chronic inflammation raised the possibility that these cells can 
contribute to initial stages of tumor development. To address this question, we used an 
experimental system where the number of IMC was regulated by the expression of 
S100A9 protein.  
In this project, we used two different models of chronic inflammation in S100A9 
transgenic (S100A9tg) and S100A9 knock-out (S100A9KO) mice. In the first model, we 
created the conditions for topical accumulation of these cells in the skin in the absence 
of infection or tissue damage using S100A9tg mice. Accumulation of IMC in the skin  
   vii 
resulted in a dramatic increase in the formation of skin tumors during epidermal 
carcinogenesis. Conversely, lack of myeloid cell accumulation in S100A9KO mice 
substantially reduced the formation of skin papillomas. The effect of IMC was not 
associated with immune suppression but with the recruitment of CD4+ T cells mediated 
by CCL4 chemokine released by activated IMC. Elimination of CD4+ T cells or blockade 
of CCL4 abrogated the increase in tumor formation caused by myeloid cells. Thus, this 
study implicates the accumulation of IMC as an initial step in facilitating of tumor 
formation, which can mediate the recruitment of CD4+ T cells via the release of CCL4 
chemokine.  
In the second model, we used inflammation-associated lung cancer caused by 
the chemical lung carcinogen urethane in combination with exposure to cigarette smoke 
referred to throughout as CS. Exposure of mice to CS alone resulted in a significant 
accumulation of cells with typical MDSC phenotype in different organs; however, these 
cells lacked immune suppressive activity and could not be defined as bona fide MDSC. 
When CS was combined with the single dose of urethane, it led to the accumulation of 
immune suppressive cells. The expansion of MDSC followed the onset of lung tumors 
development. This suggests that MDSC in this model is not the preceding factor but 
rather a consequence of tumor formation. Further studies are necessary to determine 
the relevance of targeting these cells for cancer treatment and prevention.   
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CHAPTER 1. INTRODUCTION 
 
Inflammation induces Cancer 
Inflammation has been described as a defensive natural reaction towards an 
infiltration of a foreign agent and is characterized by swelling, pain, redness and loss of 
function of the involved tissue.1 The first job of the immune system is to maintain 
homeostasis; to protect the host from the invasion of a foreign agent and to discard any 
damaged cells.  Acute inflammation is the first line of defense in the mammalian 
immune system.2  Right after an intruder invades the tissue, leukocytes enter to the 
vicinity and start secreting oxidative factors, cytokines and chemokines to kill the 
pathogen. After the environment is being cleared-up from the pathogen, healing and 
repair processes start with secretion of anti-inflammatory factors and apoptosis of 
inflammatory cells.  This process occurs in a relatively short period, from hours to 
several days.2-4  Conversely, chronic inflammation occurs when there is no resolution of 
this first onset, resulting in long-lasting effects.5   The cellular characteristic of chronic 
inflammation is the constant presence of macrophages, granulocytes, and other 
inflammatory cells that continuously secrete oxidative factors, cytokines, and 
chemokines causing DNA and tissue damage.  This persistent inflammatory 
environment can develop into neoplasia by the sustaining cell proliferation and inhibiting 
apoptosis pathways.  The critical participation of chronic inflammation has been 
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identified in different diseases including Alzheimer’s disease, arthritis, diabetes, 
cardiovascular diseases pulmonary diseases and cancer.6   
In the mid-1800s, a German scientist, Dr. Rudolf Virchow, observed 
“lymphoreticular infiltration” in neoplastic tissue and suggested a correlation between 
inflammation and tumor development.7  But it was only in the past 15 years that studies 
could prove the participation of inflammation in carcinogenesis and further clarify that 
the inflammatory microenvironment provides the essential ingredients for the 
progression of tumors.8-10 The distinctive characteristic of cancer-related inflammation is 
the incorporation of inflammatory cells, tumor cells, stroma, and inflammatory mediators 
at the site of injury with the participation of tissue remodeling and angiogenesis.10,11  
The connection of inflammation and tumor development can be viewed in two 
pathways, extrinsic and intrinsic.  In the extrinsic pathway, environmental factors such 
as microbes and viruses can initiate the pathologic process in tissues by sensitizing the 
neighboring environment to cancer development. When an infection occurs, the healthy 
immune system recruits leukocytes to the affected area to start eradicating the foreign 
agent.  When this process becomes chronic, it increases the risk of cancer 
development. 5,12  Conversely, in the intrinsic pathway, the neoplastic process starts 
with the activation of oncogenes, chromosomal rearrangement, and/or down-regulation 
of tumor suppressor genes. Other significant changes in the DNA, such as aberrant 
modification of histones, abnormal DNA methylation and deficiencies in DNA repair, can 
also lead to cancer initiation. 13,14   
A 2008 Harvard study determined that 16-18% of new cancer cases are 
attributable to preventable infections.15,16  Among infections, agents that can induce 
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cancer are Hepatitis B virus (HBV) and Hepatitis C virus (HCV), Human Papillomavirus 
(HPV) and bacterial strains from Helicobacter species.17  An inflammatory environment 
coordinates host responses against microbial infection and mediates tissue repair and 
regeneration; however, these responses can have negative impacts when the 
inflammation is not resolved in a timely manner.9  This is the case of bacterial infection, 
such as Helicobacter pylori.  Infection with H. pylori can generate inflammatory 
conditions, such as gastritis, which it is consider a very important factor in the 
development of stomach cancers.12,18,19  This inflammation consisted of the infiltration of 
leukocytes that release reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) among other genotoxic molecules.20 Generally, these molecules are potent anti-
microbial agents but can cause damage of DNA and DNA repair mechanisms in the 
infected and neighboring cells.  In order to restructure the damaged tissue, the 
inflammatory environment can provide survival and proliferative signals to the “initiated” 
cells leading to carcinogenesis.9 Moreover, H. pylori can secrete the products of 
cytotoxic-associated gene A (CagA) into gastric epithelial tissue, which can then cause 
gastroduodenal mucosal inflammation, atrophic gastritis and gastric carcinoma.21  H. 
pylori perhaps represent one of the most studied bacteria that induce chronic 
inflammation that leads to cancer development.  However, other “microorganisms”, such 
as viruses, are arising as serious promoters of cancer development. Within the past two 
decades many studies exposed the close link of virus infection and its effect on cancer 
onset. 
Viruses represent another group of infectious agents that can produce 
inflammation which leads to cancer.  Virus infection represents an estimated 15 percent 
   4 
of all cancer burdens.22 Infectious agents such as viruses can exert molecular 
mechanisms which lead to prevent apoptosis and uncontrollable proliferation.23 Some 
latent viruses can transform the cell into a malignant one.24  Viruses employ different 
ways to remain persistent and lead to carcinogenesis. One way is the activation of 
immunosuppressive mechanism through regulatory T cells (Tregs), which down-
regulate the acute inflammatory responses to kill the pathogen.25  Immunosuppressive 
mechanisms allow the host to become susceptible to other infections and to keep the 
virus inside the cells.25,26 The mechanism by which the viruses utilize cell transformation 
depends on its own genetic material. Viruses with DNA material can persist by 
integrating their genetic material into the host genome. This “new” genetic information 
can target tumor suppressor genes (p53, pRB) that are essential for making virus 
copies and cellular transformation.27  With RNA cancer viruses, like Human 
Immunodeficiency Virus (HIV) and human T cell-lymphotropic virus type 1 (HTLV1), the 
genetic material is converted into DNA first and then integrates close to an oncogene in 
the host genome.  This integration can lead to overexpression of the oncogene, which 
promotes over-growth of the cell.23,24,28   Other RNA viruses, such as  HBV and HCV, 
cannot integrate into the host DNA efficiently and instead accomplish their  tumorgenic 
ability by inducing chronic inflammation in the liver.23 This harsh environment fosters 
mechanisms and tools that can alter the DNA of the epithelial cells and thus contribute 
to malignant transformation.29   
It has also been suggested that our own microbiota, which is helpful for  
preventing diseases, can contribute to the initiation of inflammation-induced cancer.30  
For example, in 2009, Uronis et al. studied the contribution of host microbiota in the 
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development of colitis-associated colon cancer (CAC).  They treated the susceptible IL-
10 knock-out (IL10KO) mice with azoxymethane (AOM) carcinogen as a colon tumor 
initiator followed infecting with colitogenic bacteria Bacteroides vulgatus to trigger 
chronic colitis.  They found that AOM-IL-10KO mice treated with Bacterides vulgatus 
microbiota induced severe chronic colitis developed CAC, as compared to germ-free 
counterparts that remained disease-free. This is supported by the additional finding that 
MyD88 signaling, and important transcription factor for toll-like receptor (TLRs) 
expression, is involved in the development of tumor lesions in IL-10KO mice.   In this 
particular study the bacterial infection that cause inflammation can trigger early 
malignant changes induced by a carcinogen, which can help the establishment of 
uncontrolled cellular proliferation. In summary of this particular study, the presence of 
colitis is directly related to the proportion of tumor multiplicity and may act as tumor 
promoter.31 In another study that uses the same susceptible mice IL-10KO, Arthur et al. 
suggested that commensal bacteria Escherichia coli (E. coli) induce the development of 
carcinoma in the gut upon carcinogen treatment into these mice. The authors found that 
bacterial products promote tumor appearance by inducing inflammation. However, 
alteration of bacterial products could decrease tumor counts but not the inflammation 
related to the infection.  Therefore, the inflammation associated to colitis can increase 
the tumor appearance by altering microbial composition and increase the number of 
microorganisms that has genotoxic capabilities.32 These two studies provide strong 
evidence of the contribution of bacteria in carcinogenesis through the development of 
inflammation. 31,32  
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Contrary to the promoting effects that the gut microbial population has in tumor 
formation other studies showed that the same population can be necessary for a 
successful anti-cancer treatment. Recently, it was shown that commensal microbiota in 
the intestine environment can influence the outcome of tumor-targeted therapy.  Iida et 
al. showed that the therapeutic effect of combination of CpG-Oligonucleotide and 
interleukin-10 receptor (IL-10R) antibody was negatively affected by the absence or 
decrease of bacterial load in the gut in tumor-bearing mice. The antibiotics significantly 
decreased the presence of tumor-myeloid cells and its inflammatory cytokines such as 
TNF, thus promoting tumor growth.  Apparently, when mice are treated with anti-tumor 
therapy the commensal microbiota stimulate the tumor-infiltrating leukocytes to produce 
cytokines that negatively affect tumor growth. Further, they demonstrate that antibiotics 
can also have a negative effect in cancer chemotherapy. They used a platinum 
compound, oxaliplatin, which form DNA adduct and induces ROS production and 
cytotoxic T cells immunity.33,34  Treatment with antibiotic reduces the effect of the 
oxalipatin and decrease survival of tumor-bearing mice. Since ROS production is 
recognized in myeloid cells they depleted Gr1+ cells and found that the effect of 
oxilipatin was impaired in tumor bearing mice.   These data suggest that antibiotics 
could also affect the ROS production by the tumor-myeloid cells in tumor-bearing 
mice.35 
Following the same idea, another study showed how antibiotics alter the effect 
cyclophosphamide (CMX), a chemotherapy drug that induces tumor cell death by 
regulating adaptive immune responses. CMX treatment in tumor-bearing mice caused a 
dysregulation of the intestinal barrier tissue and microbial population which induce a 
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mobilization of local Gram positive- bacteria to lymphoid organs.  This dysregulation 
caused a decrease of RORgt+CD3+ T cells and CD103+CD11b+ DCs in the gut 
environment.  Further, in an in-vitro experiment they could differentiate the CD4+ T cells 
found in the spleen into Th17 and Th1 cells upon CMX treatment. Introduction of 
antibiotic into these CMX-treated mice failed to differentiate the naive CD4+ T cells into 
Th17 or Th1. This result showed the importance of the gut microbiota in the 
differentiation of T helper cells by chemotherapy treatment. Moreover, CMX was able to 
induce the pathogenic Th17 (pTh17) within the spleen in the presence of gut microbiota 
which helped decrease tumor burden. Gram-positive antibiotic in tumor bearing mice 
inhibited the anti-cancer effect of CMX thus the presence of splenic Th1 and Th17 in 
CMX-treated mice. Interestingly, they performed an adoptive transfer of in-vitro 
developed pTh17 into antibiotic-treated mice and showed that CMX could recapture its 
anti-cancer effect.36  These two studies recapitulate the importance of the host natural 
resources, such as commensal bacteria, in the eradication of cancer and highlighted the 
participation of activated leukocytes in the eradication of established tumors.   
As suggested previously, environmental factors can also influence the 
development of chronic inflammation.  It is well known that tobacco and its derivatives 
can accelerate lung cancer development.37 Studies have shown that inflammation 
caused by tobacco-associated materials can promote cancer in mice. For instance, 
Takahashi et al. demonstrated that after exposing mice to tobacco smoke, there was a 
significant increase in leukocytes population and in cytokines and chemokines mRNAs 
in the inflamed lung environment.38 Other environmental factors can also induce cancer-
promoting inflammation without directly causing genetic alterations. For example, during 
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the phagocytosis of particulates, such as asbestos and silica, reactive oxygen species 
(ROS) are secreted and can activate inflammasomes, a large cytoplasmic protein 
complexes39, which triggers the recruitment of inflammatory leukocytes and cytokines in 
the  lung.40   
Obesity, one of the major diseases of our century, has been proven to contribute 
to tumor development as well.41  Many studies suggest that obese and overweight 
populations have an increased incidence in the development of different types of 
cancer.  Obesity not only influences the tumor progression, but it can affect treatment 
outcomes, leading to an increase in mortality.42  Obesity is known to be closely 
associated with a chronic state of inflammation.  Over-weight individuals secrete more 
pro-inflammatory factors, such as TNF-α, IL-6, inducible nitric oxide synthase (iNOS), 
TGF-β, etc., than slimmer individuals.  As the adipose tissue expands, the inflammatory 
mediators can affect the homeostasis of the surrounding normal tissue.43  
Macrophages, present in adipose tissue of obese individuals, are responsible for the 
secretion of these pro-inflammatory mediators.43,44  Moreover, adipocytes, the cells that 
compose the adipose tissue, can enlarge, induce hypoxia, and secrete more 
inflammatory cytokines and chemokines that contribute to developing the inflammatory 
environment.45  Another study examined the infiltration of CD8+ T cells into the obese 
adipose tissue and presented data suggesting that these cells can also regulate 
inflammation.45  It is suggested that all of these factors, which contribute to the 
development of chronic inflammation in adipose tissues, also predispose the affected 
cells to DNA instability and activation of oncogenes; factors necessary for the initiation 
of cancer. 46   
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 It is now becoming evident that many of the factors that contribute to the chronic 
inflammation may lead to cancer development primarily by altering the intracellular and 
tissue environment to become conducive for carcinogenesis.  
 
Carcinogenesis  
Cancer is one of the leading causes of death in the United States.47   Although 
research has contributed to the early diagnosis, treatment, and prevention of cancer, 
there is still a high incidence of new cases.48 As mentioned above, epidemiological and 
laboratory studies completed in the past decade strongly support the association of 
chronic inflammation with the onset and progression of malignancy.49,50 Carcinogenesis 
is the process by which a normal cell transforms to a malignant cell by a series of 
genetic mutations. Rackoff-Nahoum described carcinogenesis as possessing six 
fundamental properties: (1) self-sufficient proliferation, (2) insensitivity to anti-
proliferative signals (3) evasion of apoptosis, (4) unlimited replicative potential (5) the 
maintenance of vascularization and, for malignancy, (6) tissue invasion and 
metastasis.9 To better assess the characteristics and function of cells in the neoplastic 
environment, these properties have been grouped into 3 phases: initiation, promotion, 
and progression.51  An important event for the development of cancer is the 
accumulation of genetic mutations in the specific tissue.  These modifications in the 
genetic materials are not only required in the initiation stage, but also are favorable in 
the subsequent progressive stages.9    
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Models of Carcinogenesis.  Cancer can originate from any part of the body.  
The multistage structure of tumor formation, which can be adapted to most types of 
cancer, arises from different tissues.51  For many decades, the induction of tumors in 
mice has been used to study the development of cancer.  It is understood that cancer 
has both environmental and genetic etiologies. Mice models are a very useful and 
controllable tool for studying these two factors independently.52   Carcinogenesis is 
generally described as a multiple-stage phase in which a healthy cell is converted to a 
cancer cell via a series of mutations. When a normal cell undergoes the first mutation, it 
is called “initiation.” If this mutation affects the expression or activation of a protein that 
promotes growth, this cell will experience accelerated growth and will enter into a series 
of intermediate states, including a pre-neoplastic stage.53 Subsequently, a selective 
clone from the neoplastic cell may experience more mutations and consequently be 
transformed into a malignant tumor cell.  This new malignant tumor cell can secrete 
factors that influence the environment and induce the other neighboring cells to go thru 
the same transformations.52,54     
The following stage is called “promotion” stage. During the promotion stage, 
various chemicals (tumor promoters) support cell proliferation and inhibition of 
apoptosis. Additionally, this stage is characterized by chronic inflammation.55,56 Tumor-
promoting agents are non-carcinogenic substance that are capable of activating the 
recruitment of leukocytes, which contribute by secreting growth factors, chemokines and 
cytokines that promote angiogenesis, more cell proliferation, and suppress host 
immunity.  Inflammatory cells also produce ROS that can promote further mutations in 
the transformed cells. All of these events promote malignant transformation, clonal 
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expansion and progression of cancer.3,56 This multi-stage model of carcinogenesis 
allows for distinction between the  initiation and promotion stages of carcinogenesis, 
which helps the analysis of the process.57 In the past decades different methods have 
been developed to study the carcinogenesis. Most of these models have in common the 
use of an initiator, a carcinogen, and a tumor promoter, a non-carcinogen agent which 
are essential elements in the carcinogenesis process (Figure 1).   
 
 
 
Figure 1. Scheme of carcinogenesis model where cells undergo neoplastic 
transformation in stage-dependent manner.   
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DMBA and TPA model. In experiments designed to study multistage 
carcinogenesis, the initiation stage is triggered by a carcinogen or an activated 
oncogene. 7, 12-dimethylbenz(a)anthracene (DMBA) is the most common topical 
carcinogen used in studies examining the biological process of carcinogenesis. 
Although this event is permanent and irreversible no tumors will grow until there is a 
promotion environment, such as the recruitment of inflammatory cells. DMBA induces 
mutations by creating metabolites that covalently attached to DNA forming DNA 
adducts.58 The main target of this carcinogen is H-ras oncogene. H-ras is located in 
chromosome 7, in an invariable site, which favored  the strong selection for the mutant 
copy.59   DMBA cause a mutation in codon 61 of the H-ras gene changing the adenine 
for a thymine which form DNA adducts (chemical carcinogen covalently bond to the 
DNA), known to cause tumorgenesis.52,60   Besides H-ras oncogene, DMBA has been 
shown to cause mutations in other members of the Ras family.  Studies made in H-ras 
KO mice with DMBA treatment showed fewer  papilloma development in these mice 
compared to WT counterparts suggesting the involvement of other Ras genes such as 
K-ras and N-ras.61   
After establishing the initiation stage, the transformed cells expand clonally 
during the promotion stage.62 Tumor promotion can be instigated by the repeated 
application of a tumor promotion agent within the vicinity of the original application of 
carcinogen. The promotion stage is characterized by the onset of chronic inflammation 
and the eventual cancer development. In this phase the mutated cells increase 
proliferation and decrease differentiation and apoptosis.63  Tumor promotion can be 
instigated by the repeated application of a chemical agent in the vicinity of original 
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application of carcinogen. The classical and most popular skin tumor promoter is 12-O-
tetradecanoylphorbol-13-acetate (TPA) also known as phorbol 12-myristate 13-acetate 
(PMA). UV light can also elicit the promotion phase.  The resulting clonal expansion of 
the initiated cells cause the hyperplasia of the epidermis.64  TPA is one of the most 
potent phorbol diester  that activates signaling thru Protein Kinase C (PKC) enzyme, 
which is a calcium activated phospholipid-dependent serine/threonine kinase.65  
Activation of PKC allows phosphorylation of transcription factors that induce the 
constant activation of oncogenes such as Ras.66  Several PKC isoforms are crucial for 
the establishment of inflammation and the increased proliferation of the malignant cell 
that are necessary for tumor development. 67,68 These chemical reagents are the most 
used in experiments to study the carcinogenesis induction and progression in animals 
that don’t harbor any mutation in the Ras gene family. However, there are other animal 
models that facilitate the studies by having the alteration in the genome that are 
expressed as mutation and are considered the initiation stage in the carcinogenesis 
model. FVBN and TgAC are mice model widely studied and use to perform experiments 
to search for information about the process of carcinogenesis. Generally, mouse model 
provide a more realistic insight about how the progress of a mutation can lead to tumor 
formation.  
 
TgAC mouse model. Among the carcinogenesis multi-stage models TgAC mice 
represent one of the best studied and the most employed transgenic mouse model for 
learning about tumor progression in a stepwise fashion.69  This animal model is used to  
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develop strategies for cancer prevention and to identify specific characteristic of the 
particular environment during tumor initiation, promotion and progression.   Interestingly, 
these mice were originally created for hematopoietic studies but a particular founder 
line, TgAC ( as used in the studies described in this dissertation), developed epidermal 
papillomas where traumas were inflicted.70 This observation was significant because it 
provided strong support for previous studies that already suggested a correlation 
between chronic irritation and wound repair with the early stages of carcinogenesis. 
These mice carry an altered oncogene that contributes to tumor progression in other 
animal models and human malignancies.71 Specifically, TgAC transgenic mice contain 
inducible v-Ha-ras oncogene that imparts the characteristic of genetically initiated skin 
to these animals.70-72 The 5’ end of this oncogene is fused to an embryonic Z-globin 
promoter which is transcriptionally activating response to wounding, UV radiation and/or 
specific chemical, thereby increasing expression of H-ras and promoting the 
development of skin papillomas (Figure 2).  In addition, in the 3’ end this construct has a 
DNA segment encoding SV40 splice/polyadenylylation which provides both RNAse 
protection and a DNA probe for identification of the transgenic mice. 70  Hence, the 
TgAC mouse line is considered an appropriate alternative to recreate and study in detail 
the carcinogenesis process since many human cancers have high incidence of 
mutations in RAS gene family. 73,74  
To achieve tumor promotion it is necessary to apply repeatedly the chemical 
agents, such as TPA, which led to hyperplasia in the epidermal area.  Also exposure to 
UV light and scratches from cage mates can lead to overgrowth of the skin in these 
mice.  These tumor promoting activities can stimulate production of growth factors,  
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Figure 2. Structure of transgene plasmid construct used to generate TgAC 
transgene mouse line by pronuclear injection 71  
 
mobilization of cytokines and chemokines, and generation of a hypoxic environment 
which is associated with tissue inflammation. 
Throughout the tumor promotion stage there is inflammatory cell infiltration, 
increased DNA synthesis, and proliferation of basal keratinocytes.75  During epidermal 
hyperplasia the group of mutated cells have a growth advantage that allows the 
selective expansion.75 The final step of the promotion stage is the development of clonal 
outgrowth known as papilloma.76 
 
Urethane and Smoking model. Lung cancer is one the deadliest types of cancer. 
Since the early 60’s, the causal relationship between smoking and lung cancer was 
established.24  Further, it become clear that exposure to second hand smoke increases  
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the chance of non-smokers to develop lung cancer.24 Also, the use of tobacco has been 
shown to be a significant contributor in the development of several other lung diseases 
related to consumption of tobacco.  Chronic obstructive pulmonary disease (COPD), 
also known as emphysema or chronic bronchitis, is an inflammatory lung disease that 
can be identified with a decline in lung function characterized by a permanent airflow 
obstruction and destruction of lung parenchyma due to inflammation.24  Although COPD 
is the third cause of death in the United Stated, it is usually preventable and treatable.  
Long term exposures to lung irritants, like cigarette smoke, improves the probability of 
developing lung cancer along with COPD.77  Therefore, it can be hypothesize that 
inflammatory pathways may be shared in the pathogenesis of lung cancer and COPD.   
Thus, experimental animal models  that  recreate the effect of smoking in humans are a 
useful tool to study tobacco effects and can further be used to perform pre-clinical tests 
of therapy and prevention.78   Moreover, this type of models can be used to analyze the 
health risks associated with  exposure to environmental tobacco smoke  by integrating 
epidemiological studies with results derived from animal experiments.79 
In most cases, murine tumors share morphological, histopathological and 
molecular characteristics with human tumors.  Murine pulmonary adenomas are well-
characterized pre tumorous lung lesions that show histological similarities to human 
non-small cell adenocarcinomas. These murine lung pre-tumorous lesions are the 
immediate precursors of malignant lung adenocarcinomas in mice.78,80 The majority of 
lung adenoma/adenocarcinoma experiments utilize single intraperitoneal injection of 
lung chemical carcinogen in a susceptible strain such as A/J mice.78  Chemical  
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carcinogens are a very useful tool to induce lung tumors in a reproducible and 
consistent way.  An ample array of chemicals with different potency can induce 
carcinogenesis of the lungs in mice including urethane, smoke components (polycyclic 
aromatic hydrocarbons and nitrosamines), metals and aflatoxin.81,82  Among the 
different lung mutagenic initiators urethane is the most common carcinogen used in 
murine lung tumorigenesis models.  Urethane can be found in tobacco leaves, tobacco 
cigarettes and even in fermented food.83,84  Urethane  is formed by the reaction of urea 
and alcohol.85  Urethane can induce the development of lung tumors in non-ciliated 
airway epithelial (Clara) or type II alveolar epithelial cells in mice.  After the carcinogen 
is introduced via the peritoneum, there is a transient decrease in the proliferation of 
these two types of lung epithelial cells– but soon after, they recover the proliferation rate 
and exceed the number of cells in control mice.82,86  Some of the genetic alterations 
found in the carcinogen induced tumor include the activation of K-ras and the inhibition 
of tumor-suppressor genes such as Rb and p53.82,87  The activation of K-ras is the one 
of the most common gene mutation found in mice and human lung cancers.  In human 
lung tumorigenesis, K-ras mutations are detected in high frequency in adenocarcinomas 
as well as their precursor stage, suggesting that the mutations within the early stages 
are indicative sign of transformation.88 Injecting urethane in AJ mouse strain can cause 
an A-T transversion in codon 61 in the K-ras gene.  Additionally, in mouse and humans 
lung tumors, the tumor suppressor genes Rb and APC were inactivated by methylation 
or by mutations. 89  Mutations in p53 were identified in carcinogenesis of the lung 
associated with tobacco smoking. However, these mutations are not frequent in the 
carcinogen-induce tumors. Studies suggest that mutation in Rb and p53 genes occur at 
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later stages when the tumor is established and ready to progress.  These mutations 
might happen as a result of DNA damage or genetic instability.87,90      
It is now very noticeable that cigarette consumption increases the incidence of 
lung cancer dramatically.  Even second-hand smokers are at great risk of development 
of chronic diseases.  Environmental tobacco smoke (ETS) is a mixture of 85% of 
sidestream smoke (SS) and 15% of mainstream smoke (MS).  The exposure to ETS 
can cause serious health concerns including asthma, bronchitis and even lung cancer 
and cardiovascular diseases.91  Initial efforts to cause tumorigenesis using cigarette 
smoke in mice indicated that cigarette smoke is poorly tumorigenic in mouse models. 
Moreover, early smoke inhalation studies performed in different animal models could 
not prove the association of cigarette smoke with the development of lung cancer.92,93  
In the past decade Witschi et al. developed a model of cigarette smoking lung 
carcinogenesis in the susceptible A/J mouse strain.  In his model they exposed A/J mice 
to ETS continuously for 5 months followed by 4 months of air exposure or rest.79  The 
smoking machine consisted of 2 components.  The first one is an automated device for 
loading, lightning, and smoking the cigarettes which enabled the mechanical smoking of 
up to 10 cigarettes simultaneously. This system uses Federal Trade Commission (FTC) 
method of puffing for 2 seconds, at a volume of 35cm3 every minute.  The second 
component is a chimney that dilutes, collects and transfers the smoke from the burning 
end of the cigarettes to the conditioning chamber.  In the conditioning chamber, the 
process of mixing and aging of the cigarettes  produce a combination of SS and MS.24,91   
Witschi et al. reported that when this combination protocol was performed in the 
smoking machine, the incidence and the multiplicity of lung tumor formation increased 
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at least 2 folds after treatment was finished.94,95   They suggested that the period of air 
exposure allowed the animals to eat regularly and diminish the metabolic rate which 
increased the chances of cancer development.  It has been studied that impaired food 
intake and high metabolic rate can decrease carcinogenesis risks.96,97 Another 
possibility is that ETS can suppress or slow down the process of tumorigenesis in 
initiated cells.96  This study allowed us to utilize the information to recreate the 
carcinogenesis model with urethane, as the initiation stage carcinogen, and the 
exposure to smoke, as the inflammation inducer in the promotion stage.  This lung 
carcinogenesis model will provide us with a tool to study to the cellular participants 
involved in the inflammation phase that can lead to development of lung cancer and 
probably other lung diseases. 
 
Myeloid cells involved in tumor promotion 
There is a complicated relationship between malignant and immune cells within 
the inflammatory environment. Immune cells along with the stromal cells come together 
to the damaged site and communicate with each other through direct contact or through 
cytokines and chemokines intervention.98  As a result of this “communication” they 
perform their functions to restore the normal state of the environment.  However,  
sometimes the presence of these activated immune cells, can push the balance towards 
the pro-cancerous state.6  Many times these immune cells can greatly contribute in the 
generation of tumor stroma, which is defined as group non-malignant cells that can 
support tumor progression and metastasis of the transformed cells.99  Members of the 
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myeloid lineage compartment are main participants in the process of tumor 
development.  In many animal and human models immature myeloid cells can stimulate 
tumor progression by supporting neovascularization, metastasis and 
immunosuppression.49,100 All these events are part of the inflammation environment that 
is created upon the arrival of these cells. Moreover, the type of insult (that is the 
mutation or the response of the immune system)  within the tissue plays a significant 
role in the progress of inflammation into carcinogenesis.2  All this together can 
determine the phenotype of the leukocytes that infiltrates into the damaged tissue and 
influence the tumor development. 
In the inflammatory environment, with the potential of tumor development, a 
diverse population of leukocytes has been found, such as neutrophils, mast cells, 
eosinophils and macrophages. These mature myeloid cell populations are loaded with 
cytokines, chemokines and other soluble factors capable of protecting the host from 
invaders.11  Moreover, many studies associate these inflammatory myeloid populations 
with the promoting forces of cancer development.  In human studies, chronic 
inflammation in the promotion stage is strongly linked to carcinomas in breast, liver, 
gastric mucosa, ovary and skin among others.11,101 During tumor promotion and 
metastasis, these myeloid cells, along with tumor cells, secrete inflammatory factors 
that allow survival, motility and metastasis.102  Possibly the best evidence of 
inflammation during neoplastic formation comes from studies in which the use of anti-
inflammatory drugs, steroids, can ameliorate the cancer risk.   There studies suggesting 
that that the use of these drugs can reduce colorectal cancer and can help with the 
prevention of gastrointestinal cancer development.103-105   A possible explanation of the 
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effect of these drugs is the ability to inhibit the enzymatic activity of cycloxygenases 
(COX1 and COX2).106  These enzymes, particularly COX2, are found to be upregulated 
in several types of cancers besides the colorectal cancer.103 COX2 can produce 
prostaglandin that can feed the inflammatory environment by modulating the immune 
system, promoting angiogenesis, regulating cellular invasion and inhibiting apoptosis, 
thereby contributing to carcinogenesis.11,107  
As mentioned before, within the inflammatory environment a variety of myeloid 
and lymphoid cells can be found, which can contribute to tumor development. In healthy 
individuals, these cells provide the protection of the organisms against various 
pathogens and tissue disruptions. Below, we will discuss some of the most important 
cells that are found in the inflammation environment.  
Bone marrow-derived cells migrate to the affected tissues in response to 
complex of various chemokines. It can amplify the presence of effector cells from 
different lineage-committed progenitors and facilitate its mobilization to the circulation. 
Many inflammatory cytokines contribute to the proliferation, differentiation and self-
renewal ability of bone marrow cells.108,109 Typically these signals play an important role 
in the maintenance of bone marrow cells but when the inflammation becomes 
persistent, are these same signals that become a threat to homeostatic environment 
and mediate cancer initiation.109   
Homeostasis within the bone marrow depends on the replacement of immune 
effectors cells by hematopoietic precursors.  Hematopoietic Stem Cells (HSCs) are a 
rare, multi-potent inactive population present in the bone marrow.  They represent only 
the 0.01 percent of the total cells in the BM and are capable of replenish the 
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hematopoietic population as they are used or become aged.  These cells supply the 
progenitors of all differentiated cell types in the blood.110,111  In response to 
hematopoietic challenges, such as hemorrhage, chemotherapy and infections, these 
HSCs can be activated to proliferate and differentiate.109,112   In the mid 90’s it was 
identified 3 groups of hematopoietic stem cells in mice: Long term-HSC, short term-HSC 
and Multi Potent Progenitors (MPP).113 Long and Short term stem cells are 
characterized by the high expression of markers c-kit, and Sca-1, very low levels of 
Thy1.1 and low or negative levels of Lin (lineage) marker.113 These cells are able to 
provide myeloid and erythroid cells necessary for survival in a BM transplantation 
experiment.114  Eventually, they start the process of self-renewal to generate more 
hematopoietic cells for the rest of the lifetime of the mice.115 However, the expression of 
these surface markers can be altered by inflammatory signals.  It was found that Sca-1 
is upregulated in the presence of IFNs and TNF116 and c-kit is down regulated during 
chemotherapy treatment.117,118 Following this stage, HSC can give rise to multi-potent 
progenitor (MPP) cells described with Lin-IL7Rα-Sca-1+c-kit+FLT3low-hiThy1-CD34+ 
surface markers.  These MMPs can differentiate into the common myeloid progenitor 
(CMPs) identified with the markers Lin-Sca-1-c-kit+CD34+FcγRII-FcγRIII- and 
subsequently into granulocyte/monocyte progenitors (GMPs,Lin-Sca-1-c-
kit+CD34+FcγRII+FcγRIII+) and megakaryocytes/erythroid progenitors (MEPs, Lin-Sca-1-
c-kit+CD34-FcγRII-FcγRIII-).111,115  GMPs and MEPs can evolve to become granulocytes, 
dendritic cells progenitors, monocytes, as well as inflammatory immature myeloid 
cells.119    
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One of the many important transcription factors that regulate the myeloid lineage 
differentiation is PU.1.  PU.1 is the product of the oncogene SP1 and belongs to E26 
transformation-specific (ETS) family of transcription factors. It has been shown that 
deficiency of PU.1 affects the cells to HSC regeneration and thus interrupts the eventual 
differentiation of CMP to mature cells.120 Interestingly, different amounts of PU.1 
regulate the differentiation stages of CMPs and common lymphoid progenitor (CLP) 
cells as well as can increase granulopoeisis.121  Even though that PU.1 is required for 
most of the early stages of mature myeloid cell differentiation, other transcription factors 
influence greatly in later stages.  Among these transcription factors are 
CCAAT/enhancer binding protein (CEBP’s), Interferon-regulatory factor 8 (IRF-8) and 
growth factor independent 1 (GFI-1) which all can activate different genes that influence 
the development of chronic inflammation.122 
All these transcription factors regulate the expression of cytokines, growth factors 
and the receptors that promote the differentiation of myeloid cells.123  The colony 
stimulated factor (CSF) family is the best characterized family of growth factors that are 
present during the hematopoietic stages and further they are expressed in later stages 
of myeloid differentiation.  This family include, among others, granulocyte-macrophage 
(GM-CSF), macrophage (M-CSF) and granulocyte (G-CSF) colony-stimulating factors. 
They can regulate myeloid cells infiltration and function in healthy individuals, as well as 
during inflammation.124 CSFs, particularly M-CSF and GM-CSF, are upregulated in the 
site of inflammation and are closely related to tumor establishment, progression, and 
invasion.  The function of these CSFs is not limited to support the inflammatory 
environment; they also contribute to the recruitment and proliferation of inflammatory 
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cells that sustain carcinogenesis.  During  the development of inflammation these CSFs 
can act as cytokines allowing communication between the myeloid cells lineage, stroma 
cells and the nearby cells promoting the establishment of transformed cells.124  CSFs 
can also influence the plasticity of macrophages in the tumor environment.  For 
example, in an in vitro study, GM-CSF treatment of TAMs with blocked M-CSF signaling 
resulted in expression of proteins that normally are upregulated in DC. 125 
It has been shown that GM-SCF can aggravate tumor development.  From a 
pancreatic cancer mouse model it was exemplified that tumor-derived GM-SCF is 
necessary to drive the development of Gr1+CD11b+ cells, which functionally can protect 
the tumor from the immune system attack. Neutralization of GM-CSF decreased the 
infiltration of Gr1+CD11b+ cells allowing cytotoxic CD8+ T cells to decrease tumor 
progression.126  Therapies designed to target these molecules can help at the onset and 
during the progression of the tumor.124,127     
Myeloid cells play a major role in constructing the environment favoring tumor 
progress and invasion.128,129 Tumor promoting agents, such as TPA, can stimulate 
enrollment of immature myeloid cells (IMCs) to the site where the carcinogen was 
applied.  After application of the chemical tumor promoter, IMCs are mobilized from the 
BM to the peripheral blood and then recruited to the site where the mutation occurred.  
These IMCs are part of the acute inflammatory cells which are the first responders to 
the altered site.56,130 Macrophages, granulocytes, mast cells are activated and proceed 
to recruit other leukocytes to the invaded tissue and start the process of elimination of 
pathogens and wound recovery.  In contrast, when homeostasis failed to be restored 
these processes remain long lasting and the same myeloid cells can develop alternative 
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functions that promote tumor growth and metastasis.130  As it was discussed before, the 
inflammatory cells are imminent participants in the progression of tumor. Elevated 
numbers of myeloid cells in the tumor microenvironment area is generally associated 
with a poor clinical outcome. Below, we discuss the most relevant information about 
these myeloid cells and its relation with the process of carcinogenesis. 
 
 
Tumor Associated Macrophages (TAM). Tumor associated macrophages are 
cells derived from immature monocytes recruited by cytokines and chemokines that are 
secreted form the inflammatory environment.129  As the name implies, these 
macrophages are found the tumor microenvironment. TAMs can promote tumor growth, 
angiogenesis, invasion and metastasis.131 TAMs are a heterogeneous population which 
expresses different phenotypes and functions depending on the tumor tissue. Generally 
in humans are identified with CD68 surface marker and in mouse with F4/80 surface 
marker.99,132  Many studies in cancer patients correlate a high percentage of 
macrophages in tumor with poor prognosis.  TAMs can influence every stage of cancer 
development, that is, initiation, growth and progression.131,133,134   Within the tumor 
environment, TAMs can produce potent angiogenic, lymphoagiogenic growth factors 
and other chemoattractants  that accelerate the neoplastic progression.135  TAMs are 
identified in two groups based in the function they performed. The first group are called 
M1 - macrophages which are activated by bacterial infections, lypopolysacharide (LPS), 
interferon-gamma (IFN-γ) or microbial-induced chemokines such as tumor necrosis 
factor alpha (TNF-α).134  These cells can up-regulate major histocompability complex 
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molecule (MHC) in their cell surfaces to increase antigen presentation, and secrete 
great amounts of IL-12 and IL-23 which can help elicit effector T cell responses. These 
cells release reactive oxygen species (ROS) and nitric oxide species that can eliminate 
pathogens as well as elicit anti-tumor cytotoxicity. 56,136  Further, they can secrete 
produce great amounts of cytokines that can induce effective adaptive immune 
responses.137,138  On the other hand, M2 or “alternatively” activated macrophages, are 
induced by  the T helper (Th) 2 cytokines, IL-4, IL-10 and IL-13, and can produce 
several growth factors that activate the tissue repair process and suppress adaptive 
immune responses.139  These cells are found in more protumorgenic hypoxic 
environment and can downregulate inflammatory and type 1-immune responses and 
can start the process of neoangiogenesis.136,138   Anti-inflammatory cytokines such as 
IL-4, IL-13 and regulatory biochemical, such as glucorticoids, can induce polarization of 
macrophages towards M2 phenotype and can prevent classic macrophage activation 
and function.140,141  Further, tumor cells can help M2 macrophages induce angiogenesis 
and immunosuppressive function by upregulating TGF-β, IL-10 and IL-1 receptors.  
Therefore, the tumor environment can interfere with the anti-tumor attack from the 
immune system and promote invasion and metastasis.141,142 In addition, M2 
macrophages can produce matrix metalopeptidase 2 (MMP2) which can contribute to 
tumorgenesis and metastasis, in addition to the immunosuppressive chemokines, 
including C-C ligand 17 (CCL17), CCL18 and CCL22 that may favor the T regulatory 
(Tregs) recruitment.141  Previous studies found that high levels of M2-type macrophages 
correlated with an immunosuppressive environment in patients with fibrosarcoma and 
ovarian cancer.143   M2-TAMs block anti-tumor immunity by eliminating M1 macrophage 
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mediated innate immune activity and sabotaging cytotoxic T lymphocyte (CTL) 
activation. Moreover, these cells are incompetent antigen presenting cells and can 
attract Tregs which adds to the immunosuppressive environment.144 This functional 
plasticity of macrophages depends on the environment. The presence of TAM is 
elevated at late stages of tumors and is associated with poor survival.139,145  
 
 
Myeloid-Derived Suppressor Cells (MDSC). These cells represent a 
heterogeneous population of pathologically activated myeloid cells that includes 
precursors of neutrophils, macrophages, DCs, and cells on earlier stages of myeloid 
cells differentiation.99,146 It has been shown that these cells can influence the 
development of chronic conditions, like autoimmunity, infectious diseases and 
cancer.147-149  The first observations of these cells described their accumulation in the 
BM and spleens of tumor-bearing mice and peripheral blood of cancer patients.150,151  
MDSCs are characterized by high plasticity152-154 described in more details below.  
In healthy individuals immature myeloid cells (IMCs) differentiate to functional 
macrophages and DCs but in cancer and many chronic diseases, these IMCs can 
expand and acquire MDSCs characteristics.148,155  In mice, these cells are defined as 
Gr1+CD11b+ cells. Gr1 includes Ly6C and Ly6G epitopes and CD11b, which is a αM-
integrin marker of myeloid cells.147,156  In humans, phenotypic identification of MDSC is 
more complicated due to the lack of a single marker and the diversity of the cancer 
being studied.  Despite this, generally, human MDSCs express CD11b and CD33 and 
other granulocytic markers with the absence of DC, macrophages and other 
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lymphocytes markers.157,158  Further, two subsets of MDSCs have been identified in 
mouse tumor models, characterized by these cells’ different morphology and surface 
marker expression.159  One of these subsets are Granulocytic (G-), also known as 
polymorphonuclear (PMN-) MDSCs, which have a morphology similar to granulocytes 
and monocytic (M-) MDSCs which have its morphology similar to monocytes. G-MDSCs 
can be characterized by its expressed markers CD11b+Ly6G+Ly6Clow, and M-MDSCs 
expressed CD11b+Ly6G-Ly6Chigh. Additionally, these cells have different suppressive 
activities.  G-MDSC uses ROS and little nitric oxide (NO) to facilitate suppressive 
functions and M-MDSC up-regulate a series of cytokines but primary use inducible nitric 
oxide synthase (iNOS) and arginase to perform its immunosuppressive activity.147,159 
Overall, MDSCs are characterized by their potent immunosuppressive activity and the 
ability to promote tumor angiogenesis, tumor cell invasion, and metastasis.99  Another 
mechanism by which MDSCs execute their suppressive activity against T cells is by 
sequestering cysteine an important amino acid for T cell activation. DC and 
macrophages are important providers of this essential amino acid.  In the presence of 
MDSCs cysteine is reduced and is not returned to the environment thus limiting its 
availability to T cells.160   Other mechanisms of suppression by these cells include 
secretion of TGF-β, the induction of regulatory T cells,  down-regulation of L-selectin 
expression in T cells and up-regulation of cyclooxygenase and prostaglandin E2.161 
MDSCs have been implicated in many types of cancer and now are getting recognition 
for its participation during chronic inflammation.162  MDSCs can corrupt immune 
surveillance and block the healthy immune system from eradicating newly transformed 
cells.  When chronic inflammation is developing, many factors secreted by the 
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inflammatory cells to the environment can promote recruitment and accumulation of 
MDSCs from the bone marrow.154,162 Inflammatory mediators such as growth factors 
(GM-CSF, G-CSF, VEGF, TGF-β), pro-inflammatory cytokines (IL-1β, IL-6, IL-13, IFN-γ 
and TNF-α) and prostaglandin E2 are known to be expressed by mutated cells in 
chronic inflammation which in turn can recruit immature myeloid cells.49,162 However, it 
has been noted that even in decreased amounts of these inflammatory mediators 
MDSCs can be found in the inflammatory environment suggesting that other molecules 
might play an important role in the mobilization of MDSCs during inflammation.163 For 
example, chemoattractant proteins, such as S100A9 and S100A8, are important 
recruiters of MDSCs. Tumor environment and MDSCs itself can secrete these proteins 
as heterodimers which bind to the corresponding receptor and cause retention of the 
accumulated MDSCs providing a positive feedback for the suppressive function of these 
cells.  Moreover, these proteins facilitate the IMCs conversion into MDSCs in the 
immunosuppressive environment.163,164 Several molecular mechanisms govern the 
participation of MDSCs in pathological conditions.165  Signal transducer and activation of 
transcription 3 (STAT3) represents one of the transcription factors that play an important 
role in the accumulation, differentiation and function of MDSCs.165,166 Activation of 
STAT3 pathway abrogates differentiation of immature myeloid cells into a mature state 
which promotes MDSC accumulation.167  Further, STAT3 is, in part, responsible of the 
suppressive capacity of MDSCs.  ROS is induced by the transcription of Nox2 which is 
directly upregulated by the activation of STAT3.168  Another transcription factor that is 
becoming noticeable in the MDSCs accumulation and function is NFκB. Upon ligand 
binding to toll-like receptor 4 (TLR-4) there is an activation of NFκB-MyD88 signaling 
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pathway. This is constant with the infiltration of MDSCs in the inflammation and 
eventual cancer development since the ligands and molecules that activate the TLRs 
are very abundant in this environment. Activation of TLR4 in MDSCs contributes in 
tumor progression by stimulating the immunosuppressive environment which prevents 
the anti-tumor immunity.169    
It is recognizable the importance and the participation of MDSCs in the regulation 
of pathological conditions. It is very necessary to clearly understand the molecular 
activities that drive the polarization of MDSCs to a suppressive stage. This 
understanding will facilitate the development of more accurate therapies in pathological 
disorders.    
 
 
Tumor Associated Neutrophils (TAN) and their relationship with PMN-
MDSC. Historically, polymorphonuclear neutrophils (PMN) were considered as 
peripheral element in tumor progression. Traditionally, PMN’s function was considered 
as largely confined to the protection of organism from invading pathogens. PMN 
comprise 50-70% of all circulating leukocytes. They are first leukocytes to reach the 
damaged tissue.170,171 PMN are characterized by extensive network of different types of 
granules that store various proteases and needed to perform antimicrobial functions.172 
PMN are specialized on phagocytosis and killing of the invading microorganisms and 
the release of pro-inflammatory factors, such as IL-1β, TNFα and IFNs, defensins, 
etc.173,174  
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Tumor stroma can secrete cytokines that promote myelopoiesis and extravasion 
of immature neutrophils.175  For example, upon activation of K-Ras oncogene there is 
an upregulation of CXC chemokines which cause accumulation of neutrophils and 
promotion of tumor growth in the lungs.176   In human cancer, tumor-derived CXCL8, 
CCL3, CXCL6 and in murine cancer models CCL3 and CXCL6 are shown to promote 
PMN migration through their potent chemokine action.175 Within the malignant tissue 
neutrophils can contribute to angiogenesis, cell proliferation and metastasis by secreting 
bioactive molecules. Human neutrophils secrete CXCL8 and their murine counterparts 
secrete CXCL1 and CXCL2, CXCL10 and CXCL11 and hepatocyte growth factor 
(HGF), which promote angiogenesis in different cancers.177,178 Additionally, the 
secretion of CXCL8 by PMN contributes to angiogenesis and possibly can induce a 
positive feedback for additional neutrophil infiltration within the environment.177    
The existent of two types of tumor infiltrating neutrophils (TAN) in cancer was 
suggested as a reflection of the different degrees of activation and that is fully 
activated/antitumoral, known as N1 TANs and weakly activated/protumoral, known as 
N2 TANs.175,179   N1-type functions include immunoactivating cytokines and 
chemokines, lower levels of arginase, a higher capacity of killing tumor cells and 
activating cytotoxic T cells (CTL). N2 TANs secretes cytokines, chemokines and other 
inflammatory molecules can both help in the tumor progression and attract other 
inflammatory cells that strength the tumor establishment and invasiveness.171,175  One of 
the major contributors to this plasticity is TGF-β, which favors the polarization towards 
N2 TAN and prevents the generation of N1 TANs.180 TANs and other bone marrow-
derived cells contribute to tumorgenesis by secreting proteases such as matrix 
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metalloproteinase 9 (MMP-9).181 MMP-9 is involved in various carcinogenesis models 
by upregulating secretion of VEGF and promoting angiogenesis.   
Participation of neutrophils has been described in several acute diseases like 
lung and spinal cord injuries as well as in chronic diseases such as COPD, rheumatoid 
arthritis and asthma.170  Recent data have demonstrated that these neutrophils can also 
participate further in the inflammation process leading to cancer development.182 
Recruitment of TANs into the tumor environment is mediated by chemokines and 
cytokines secreted by transformed cells and other cells from the same environment.  
The identification of chemokines together with neutrophils within the tumor environment 
strongly suggests that these neutrophils are supporting tumor growth and not 
performing anti-tumor functions.176,183 In early stages of tumor this cells have been 
associated with genetic instability. Further, in the subsequent stages of cancer 
progression neutrophils can secrete different molecules that supports the survival of the 
tumorous environment.184  In many established human cancers, analysis of peripheral 
blood neutrophils counts could help predict the outcome of the disease.  But in many 
cases this counts needs to be validated with the PNM counts in the tumor site.182  
Introduction of the concept of MDSC in recent years raised the question whether 
TAN are in fact PMN-MDSC. These cells share the same phenotype. To elucidate this 
Youn et al. investigated PMN-MDSC from tumor-bearing mice and PMN from tumor-free 
mice.  In this study they sorted CD11b+Ly6G+Ly6Clow cells from spleens and from 
peritoneal cavities after casein-induced mobilization. One of the first differences they 
address was in the maturing state. G-MDSC is described among the MDSC population 
which by definition they are present in an immature state contrasting neutrophils that 
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are described as fully matured population of myeloid cells.  Adding to this description 
the scientists found that G-MDSC express higher levels of CD115 (M-CSF receptor) 
and CD244 (expressed in NK cells and in some hematopoietic stem cells) in different 
tumor models than in neutrophils which these markers are practically absent.  These 
markers may contribute the characterization of the immature state of G-MDSC versus 
neutrophils.  In terms of activation when G-MDSCs were expose to LPS these cells 
acquired immunosuppressive activity against T cells. However, neutrophils did not show 
any immunosuppressive activity, in fact these cells promoted T cell function.  Important 
to note that in in-vitro studies splenic G-MDSCs in the presence of growth factors can 
differentiate into neutrophils within 24 hours.  However in an experiment with BrDU they 
identified that most of the cells within the tumor environment express CD115 and 
CD244 suggesting that tumor-derived factors promote constant influx of G-MDSC and 
prevents to differentiate into neutrophils.  This study suggests that G-MDSCs are 
suppressive precursors of neutrophils.   Within the tumor environment the possible 
differentiation of these precursors’ cells to mature neutrophils is blocked and 
alternatively they acquire an immunosuppressive characteristic.178    
Generally, myeloid cells populations serve as an important link between innate 
and adaptive immunity to counteract invader pathogens as well cancer cells.  But also it 
has been studied the contribution of these cells in different stages of cancer 
development. In addition tumor infiltrating myeloid cells can alter potential anti-cancer 
therapy which jeopardizes the patient responses. It is no doubt that future and better 
studies of these population are necessary for better characterization and understanding 
of  their function not only cancer patients but in individuals carrying other health 
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disparities.  Targeting and/or reprogramming these specific populations will improve the 
efficacy of cancer therapies and other chronic diseases.     
 
S100A9 and S100A8 Proteins. The role of S100A8/A9 proteins have been 
studied in multiple diseases, from acute and chronic inflammation to cancer 
development and metastasis.185 S100A9, also known as Calgranulin B or myeloid-
related protein 14 (MRP14), is a member of a large family of S100 Ca-binding proteins 
that contains 2EF-hand motifs.186  It can form a functional heterodimer with S100A8 
protein (S100A8/A9, calprotectin) and is involved in a diverse intracellular processes, 
including arachidonic acid transport, NADPH oxidase activation, cellular signaling 
cascades, and cytoskeleton rearrangement.164,186  S100A9 is a pro-inflammatory 
cytokine that can translocate into the cytoskeleton of myeloid cells and recruit 
leukocytes to the sites of inflammation.185,186  Further these proteins have been 
extensively related to cytokine-like and chemokine-like functions in the extracellular 
environment. High levels of S100A8/A9 have been detected in many cancers as well as 
in chronic diseases.162,187-189 The most notable receptors for S100A9 proteins are Toll-
like receptor 4 (TLR4) and receptor for advance glycation end products (RAGE).186,190  
Within the inflammatory microenvironment S100A9 is highly expressed by neutrophils 
and epithelial cells.187 S100A8/A9 proteins contribute to the infiltration of additional 
leukocytes from the circulation, which can enhance the immunosuppressive 
environment and potentially facilitate tumor development.154,163,191 Sinha et al. 
demonstrated that the tumor environment can induce infiltration of MDSCs by secreting 
S100A8/A9 complex. This complex binds to the RAGE receptor present in the immature 
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myeloid cells and signals through the NFκB pathway promoting migration and additional 
expression of S100A8/A9 heterodimer by MDSCs.163  Moreover, S100A9 protein has 
been linked to defective maturation process of myeloid cells.  Upregulation of S100A9 
protein is seen at early stages of myeloid lineages differentiation and expression of 
CD11b in neutrophils, monocytes and macrophages.186,192.  Tumor cells are capable of 
interrupting the differentiation of myeloid cells by secreting VEGF, IL-6, M-CSF, and 
GM-CSF.  In line with these facts, Cheng et al. demonstrated that VEGF upregulated 
S100A9 expression in HPC. Transgenic mouse was created where s100a9 was 
expressed in hematopoietic cells under control of the H2K-promoter/enhancer and 
Moloney MuLV enhancer/poly(A) site.167,193 To trace expression of transgene, GFP 
gene was introduced behind an IRES sequence to allow for separate translation.167 
(Figure 3)  
 
Figure 3.  Vector used for generation of S100A9tg mice by microinjection to 
fertilized FVB/N zygotes. 167 
 
 
Several experiments were performed and suggests that overexpression of this 
protein can enhance the progression of tumor in mice.  They were able to show that the 
overexpression of S100A9 protein accelerates tumor growth.  In an in-vitro study  HPCs 
from S100A9tg (GFP+Tg) mice cultured with LPS generated more Gr1+CD11b+ IMC 
than HPCs from WT mice, and significantly decrease differentiation of  other myeloid  
   36 
cells phenotypes, CD11c+ and Gr1-F4/80+.  These results suggest that upregulation of 
S100A9 protein in an inflammatory environment could induce acceleration of tumor 
growth and accumulation of IMCs at the expense of differentiated DCs and 
macrophages.167  
Further, in an in-vivo experiment they showed that over expression of S100A9 
not only affected tumor growth, it also increased number of Gr1+ cells in response to 
inoculation of mice with tumor cells or CFA. Tumor progression was also studied in the 
absence of S100A9.  For these experiments they used S100A9KO mice. Manitz et al. 
generated these S100A9-deficient mice by replacing the translational start site of the 
entire coding region of S100A9 protein with neomycin cassette thus deleting the starting 
codon. The absence of this protein deregulates the expression of CD11b in neutrophils 
which corresponds to the inability of these cells to response to tumor secreting factors in 
vitro.194  In line with these findings Cheng et al. hypothesize the tumor progression is 
affected in the absence of S100A9. Indeed, this study demonstrated that the absence of 
this protein in tumor-bearing mice can delay tumor progression.  To explain this 
phenomenon, they showed that HPC failed to differentiate into DC in the presence of 
tumor-cell conditioned media (TCM) from EL4-tumor bearing mice.167    
Overall, these results suggest that the bone marrow derived-IMCs that participate 
in the tumor development itself are Gr1+CD11+ cells and no other myeloid cells 
phenotype. Since early stages of cancer development are characterized by 
inflammation with upregulation of molecules, such as S100A9, it is intriguing to 
investigate if these same IMCs are required to start the process of tumor formation. 195-
197  During inflammation-induce cancer other cells from the immune system, specifically 
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from the adaptive immune, help to set up the environment for tumor establishment. 
These cells, called lymphocytes, can actually suppress the anti-tumor surveillance or 
block cytotoxic attack and induce more cytokines that cooperate in the inflammation 
process.198-200    
 
 
Adaptive Immune System contributes to Inflammation induced Cancer 
Lymphocytes are critical element of cancer immunosurveillance, capable of 
recognizing malignant changes in cells and execute effector mechanisms before the 
tumor onset.201 Adaptive immunity is also important for promotion of the inflammatory 
environment. An innate immune response in the chronic inflammation activates 
effectors lymphocytes via the direct contact with APC. In lymphocytes antigen-specific 
receptors are the consequence of random gene rearrangement that allowed a more 
extended and flexible repertoire of responses.202,203 In contrast, myeloid cells express 
germline-encoded receptors which provide a invariable function.203 The classical 
protective function presented by lymphocytes is cytotoxicity via granzyme/perforin 
system or engaging death receptor. 204 This effect can be further amplified by the 
secretion of pro-Inflammatory cytokines IFNγ and TNFα mainly by T helpers 1 (Th1) 
cells.205 Studies characterizing cells during chronic inflammation and tumor formation 
revealed the complex heterogeneity of lymphocyte and myeloid nature.201   
It is now accepted that the inhibition of adaptive immune system can contribute to 
cancer development. This occurrence is mediated by inhibition of CTL, antitumor 
chemokines and cytokines, accumulation of regulatory T cells and B cells.206 Animal 
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models experiments provided mixed reports regarding the absence of lymphocytes 
during cancer development.  For example, in a study of HPV16 cervical carcinogenesis, 
elimination of CD4 T lymphocytes resulted in a slight delay on tumor growth; however, 
in the same model, female mice treated with estrogen therapy for the elimination of the 
CD4 T lymphocyte population resulted in tumor enhancement and predisposition to 
cervical carcinoma, as compared to the control group.207  The roles of the immune 
system can become hazardous during chronic inflammations as adaptive immune 
responses may cause 1) ongoing activation of innate immune system 2) antibody 
accumulation resulting in additional recruitment of innate immune cells and 3) T 
lymphocyte dysfunction instead of activation.208 Modified T cells and B cells can 
regulate aspects of myeloid cells by altering their basic biology which consequently can 
control or mismanage the immune response.209  Studies showed that depending on the 
tumor environment and the differentiation stage of lymphocytes, these cells have 
exchange antitumor and pro-tumor capabilities.210 
 
The development and expansion of T lymphocytes   
T lymphocytes undergo several stages of differentiation before they acquire the 
mature and/or effector phenotype.210 Lymphopoiesis takes place in the BM and in the 
thymus, which are called the central lymphoid tissue.211  Hematopoietic stem cells 
(HSC) differentiate to the common lymphocyte progenitors (CLP) but also can give rise 
to early T-lineage precursors (ETP). Although CLP can give rise to T cells precursors, it 
is the ETP that give rise to the T cell precursor that migrates from the BM to the 
thymus.212  Once in the thymus, these precursors received a series of signals from 
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stroma, which include up-regulation of Notch1 receptors. Notch signaling helps early 
precursors of T cells to determine the nature of the T cell receptors (TCR) expressing 
alpha/beta (αβ) or gamma/delta (γδ) and CD4+ or CD8+ T-cell commitment.213 Before 
they acquired mature markers, thymocytes go through several stages of CD4/CD8 
double negative cells.  While migrating to the outer cortex of the thymus, they 
upregulate CD4 and CD8 molecules. During this double positive (DP) stage, Rag and 
TCR genes start to express. Subsequently, the process of differentiation to CD4 or CD8 
single positive cells occurs, resulting in the correct assemblage of the TCR and ligand 
affinity to the major histocompability complex (MHC) present on APC.214 After 
concluding the positive selection, the thymocytes are ready to move to the periphery as 
naïve lymphocytes.215  The two major lymphocytes subset, CD4 T cells (or T helper 
cells, Th) and CD8 T cells (cytotoxic T lymphocytes, CTL) are activated upon 
recognition by their TCR of non-self-antigens presented by MHC class II or MHC class I 
respectively.216   Activation of T cell requires essentially two signals that happen at the 
same time. Signal 1 is the recognition and engagement of the TCR/CD3 (on the T cell) 
with the MHC/antigen (on APC) and signal 2 is the interaction between co-stimulatory 
molecules B7 on APC surface with CD28 on T cells surface.217 It has also been also 
suggested that a third signal, provided by inflammatory molecules, is necessary for 
providing for the maturation of effector T cells.218 219,220  Pape et al. showed that clonal 
expansion of CD4 T cells is enhanced by the administration of IL-1β and TNF-α 
compared to cells stimulated with antigen only.  Previously it wasn’t clear if IL-1β can 
directly improve the clonal expansion of CD4 T cells or if was the effect on APC by 
upregulating costimulatory molecules.218,221 Later it was demonstrated that signal 3 
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provided chromatin remodeling to maintain transcription of numerous genes required for 
survival, differentiation and effector function of T cells.219   
 
T cells presence in Chronic Inflammation and Cancer  
The adaptive immune system plays an important role in maintaining tissue 
homeostasis.  Communication between the two branches of the immune system, the 
innate and the adaptive, is performed by a complex interaction of the distinctive immune 
cells of each branch, their soluble factors and the environment where they are 
located.198,209  In an acute inflammatory response the innate immune cells can efficiently 
coordinate the adaptive immune response that leads to a rapid healing of the tissue. 
However, it is known that in chronic inflammation, the innate immune system can 
deregulate adaptive immune cells and rendering the overall immune response to tissue 
destruction.10,137    
The presence of leukocytes in the tumor microenvironment is a common feature 
of many cancers.  Many studies with cancer patients suggested that infiltration of T 
cells, specifically CD8 phenotype, can prolong survival and improve the outcome of the 
patients.222-224 However some studies showed that the excessive presence of immune 
cells such as macrophages and CD4 T cells is associated with poor prognosis.225-227  
CD8+ CTL have a well-described function in the tumor environment. Normally, these 
cells have a specific role eliminating tumor cells. Clinical studies found that infiltration of 
CD8 T cells correlated with good prognosis, although this was not a definitive 
conclusion.227 This conclusion was made based on the assessment of secretion of IFN-
γ in the tumor environment and/or by directly performing cytotoxic tests in limited 
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number of patients. 228 CD4+ T helper lymphocytes have a more complex role in the 
tumor development. Daniel et al., in a 2003 study, used K14-HPV16 carcinogenesis 
model to test the possible role of CD4+ T helper cells within the inflammation 
environment.229 K14-HPV mice expressed human papilloma virus 16 (HPV16) 
oncogene under control of human keratin 14 (K14) promoter leading to multistage 
carcinogenesis.230 Depletion of CD4+ T cells in this model delayed tumor development.  
Interestingly they found that CD4+ T cells influenced the development of neoplasm 
during inflammation mediated by a Staphylococcus infection.229 These findings stressed 
the importance of CD4+ T cells infiltration in the inflammation process that could 
enhance malignant progression.229,231  In contrast, Rao et al. observed that transfer of 
pro-inflammatory CD4+ T cells to APCMin/+ transgenic mice enhanced the development 
of mammary tumors.232  APCMin/+ transgenic mice are designed to develop intestinal 
adenomas similar to humans that carry the APC mutation. In female APCMin/+ mice this 
mutation resulted in the development of mammary tumors.232,233 The development of 
tumors was attenuated by co-transfer of the inflammatory CD4+T cells with the 
regulatory CD4+ T cells or by neutralization of TNFα.232 This paradoxical observation 
can be explained by the deficient ability of these proinflammatory CD4+  T cells to 
support humoral immunity and by the lack of help to CD8 CTL.234  All these studies 
suggest that different subsets of CD4 T cells might have a distinctive role in tumor 
development. CD4+ T helper cells represent a heterogeneous population of cells that 
includesTh1, Th2, Th17, Th22, Tregs, and other types of cells.  
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T helper 1 (Th1) and T helper 2 (Th2) cells. The differentiation of uncommitted 
CD4+ T cell to Th1 type requires exposure to IFN-γ and IL-12.235 Th1 differentiation is 
regulated by the transcription factor T-box (T-bet), which also can suppress the possible 
development of other types of Th cells.236 Upon differentiation, effector Th1 secrete 
more IFN-γ together with other pro-inflammatory cytokines, such as TNF-α and TNF-β, 
which are crucial in anti-tumor immunity as well as in the elimination of bacteria, viruses 
and parasites among other pathogens.237 Activation of Th1 can induce up-regulation of 
MHC class I and II molecules in APCs, which are necessary for adequate function and 
durability of CD8 effector cells.238  A recent study proved that Th1 can actually acquire 
MHC1/peptide complex from DCs and drive the activation and function of naïve CD8 
cytotoxic T cells. They further did an adoptive transfer of CD4 Th1 cells together with 
CD8 cytotoxic T cells and successfully reduced well-established EG7 tumor size in 
mice.205  
There is very limited information about the participation of Th1 cells in the 
process of tumor formation. On the contrary, this phenotype is being described with 
anti-tumor capacity and not as favoring carcinogenesis. Early studies in experimental 
autoimmune encephalomyelitis (EAE), a model of autoimmunity in mice, showed IFN-γ-
secreted Th1 cells caused the pathology of the disease.239,240  Later, the critical role of 
IL-12p40 was found, since the absence of this subunit protected the mice from various 
immune disorders including EAE.  Further studies showed that the deletion of IL-12p40 
subunit cause a decrease in IL-23 and not IL-12.241,242  IL-23 is a cytokine secreted by 
Th17, T helper cells with pro-inflammatory features.243  Th17 is an IL-17-producing 
CD4+ phenotype and is going to be discussed in details below.  
   43 
The plasticity of Th lymphocytes became focus of attention lately. For example, 
some reports showed that CD4 T helper cells can secrete IFN-γ and IL-17 in inflamed 
tissues.244 In Th1 polarizing conditions Th17 is capable to convert into Th1 in vivo and in 
vitro. Interestingly Th1 is not capable of switching to IL-17 secreting phenotype.245,246  
Adoptive transfer of polarized Th17 cells was performed in NOD mice which promote 
pancreatic inflammation. However, it was shown that when these cells converted into 
IFN-γ-producing Th1 it manifested in increased diabetes.247  These findings suggest 
that the cytokines secreted by different CD4+ Th cells cooperate in different states of 
inflammatory conditions.   
As mentioned above, Th1 cells are associated with anti-tumor immunity since 
they play a central role in activation of cytotoxic T cells (CTLs). However, in a colon 
cancer study it was found a decreases expression of Th1 cytokines versus an elevated 
expression of Th2 related cytokines.248-250  Th2 produces IL-4 and IL-10, cytokines that 
are associated with immunosuppression.251  This could be explained by the presence of 
polyps or adenomas, which are characterized by chronic inflammation.252  In healthy 
individuals, the process of tissue restoration is characterized by the production of 
suppressive cytokines, as a negative feedback mechanism in response to the release of 
pro-inflammatory cytokines trying to destruct the foreign antigen. This “new” 
environment allows the transformed cells to spread and metastasized. The imbalance of 
Th1 and Th2 cytokines found in colorectal cancer has several mechanisms including the 
synthesis of endogenous histamines and the induction of a cyclooxygenase enzyme in 
immunosuppressive environments.253,254  
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Th2 differentiation essentially requires the exposure of naïve CD4+ T cells to IL-4 
and IL-2. The master regulator of Th2 differentiation is GATA-binding protein 3 
(GATA3). 255  GATA3 expression occurs through the up-regulation of STAT6 after the 
engagement of IL-4 receptor.256  GATA3 antagonizes Th1 development.256,257 Contrary 
to Th1 response, Th2 cells response is associated with humoral immunity, in which high 
levels of antibodies are generated against extracellular pathogens such as helminthes 
and nematodes.258 Th2 immunity is associated with the infiltration of eosinophils, 
basophiles, and mast cells, which can mount a potent response against foreign 
pathogens.259,260  Th2 cells can also elicit inflammation, especially in the lung. 
Excessive Th2 responses are found in the mucosal tissue within the lung, which 
provoke the development of atopic asthma and allergy. Cytokines IL-5, IL-4 and IL-13 
secreted by Th2 cells can induce the infiltration of eosinophils in the lung.261   
Interestingly, the combination of IFN-α secreted by Th1 and CD8+ cells in conjunction 
with Th2 cytokines can contribute to the maintenance of the inflammation within the 
lung. 262 
Recently it has been proposed that Th2 type inflammation can facilitate tumor 
growth and is related to poor prognosis in cancer patients.263,264. Breast and pancreatic 
cancer are heavily infiltrated by Th2 cells and their signature cytokines IL-4 and IL-13.265 
The studies proposed that upon activation with pro-inflammatory cytokines cancer-
associated fibroblast release thymic stromal lymphopoietin (TSLPs) which act as DCs 
and allowed Th2 polarization. Activation of Th2 promotes the differentiation of infiltrating 
macrophages to the tumor-promoting M2 phenotype thus favoring the environment to 
induce carcinogenesis.265,266   Moreover, many studies show that alteration in the 
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Th1/Th2 ratio within the tumor environment is closely related to accelerated 
development of tumor and poor survival of the patient.267,268  
 
T helper 17 (Th17) cells. Th17 CD4+ T cells were identified during the studies of 
chronic inflammatory diseases such as, experimental autoimmune encephalomyelitis 
(EAE) and collagen-induce arthritis (CA).269,270 Th17 cells differentiation happens when 
naïve CD4 T helper cells are exposed to the pro-inflammatory cytokine IL-6 and anti-
inflammatory cytokine TGF-β. 271 In human and in mouse models is being shown that 
IL1-β together with TNF-α can also facilitate Th17 differentiation.272  In vitro activated 
DCs can secrete IL-1β and TNFα, which together with IL-6 can drive the differentiation 
of Th17 but only in the presence of TGF-β.273 As the nomenclature implies, these cells 
secretes cytokine IL-17 (IL-17A) but also secretes IL-17F, IL-21, IL-22, TNF-α, IL-6 and 
GM-CSF among other factors.274,275   It is important to note that IL-23 have been 
mistakenly implicated in differentiation of Th17 but studies confirmed that this cytokine 
is required for expansion and survival of Th17 and is not necessary for initial 
differentiation.276   IL-21 has more importance in the differentiation process of Th17.   
This cytokine can induce the development of Th17 when IL-6 is absent or is at low 
levels.  It is assumed that IL-21 acts as positive feedback for maintenance the precursor 
pool of Th17.  Thus, under IL-6 depleted circumstances IL-21 is an important support of 
Th17 responses and during development of inflammation.277 Retinoic acid receptor-
related orphan receptor gamma-t (RORγ-t) is been reported as the master regulator of 
differentiation of Th17.278  IL-6 and TGF-β promote Th17 differentiation by upregulation 
of RORγ-t and suppression of T-bet and GATA3 , Th1 and Th2 respective transcription 
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factors.  The target genes of RORγ-t and the mechanism that induce IL-17 production 
on these cells remain unclear.279 Recently, another transcription factor of the ROR 
family, receptor-related orphan receptor alpha (ROR-α), was implicated in the 
development of Th17.   It was suggested that RORα might act cooperatively with RORγt 
or as a compensation factor to Th17 since differentiation of these cells wasn’t affected 
in the absence of RORα. 276 
A Th17 cell function has been strongly associated with the development of 
autoimmune diseases.280 The main physiological role of Th17 cells is to mount immune 
defense against certain bacteria, fungi, viruses and ciliates that invade the host.  These 
cells have been implicated in immune defense of mucosal areas such as in the gut, skin 
and lungs.281  IL-17 is a potent pro-inflammatory mediator in tissue and has a pleiotropic 
effect on tissue cells and other immune cells.  This cytokine can attract neutrophils by 
inducing potent inflammatory cytokines and chemokines such as IL-6, IL-1-β, IL-8, TNF-
α, monocyte chemoattractant protein-1 (MCP-1) and can upregulate Intercellular 
Adhesion Molecule (ICAM) in keratinocytes, endothelial cells, epithelial cells and 
fibroblast.282 Th17 cells infiltration was observed in lupus erythromatosus, asthma, 
human cancer, as well during allograft rejection and infections.283   Coccia et al. 
identified synergistic activities of IL-1β and IL-23 in promoting pathogenic innate and 
adaptive immune responses in the gut. Further, they were able to identified Th17 cells 
derived from a T cell transfer model of colitis. Th17 cells were demonstrated to play an 
important role in sustaining the inflammatory environment within the colon and 
stomach.284   IL-17, produced by Th17 cells, can contribute to cancer development by 
inducing angiogenesis, recruitment of myeloid cells and promoting other factors that are 
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required for cancer establishment.285,286  It was documented that the presence of IFN-γ 
secreted by Th1 can deplete Th17 development.287,288  However, the coexistence of Th1 
and Th17 cell populations has been reported in many autoimmune diseases.289,290  
Recently, it was demonstrated that in psoriasis inflammatory model Th1-derived IFN-γ 
can activate secretion of IL-23 and IL-1β by resident APCs. This resulted in an 
expansion of memory Th17 and depletion of Th1. Therefore during the development of 
an inflammatory environment Th1 differentiation was diminished and was shifted 
towards a Th17 type chronic inflammation by APC derived IL-1β and IL-23.285  
Moreover, it has been demonstrated that Th17 cells can accelerate the tumor formation.  
In a two- stage carcinogenesis study, induced by DMBA/TPA treatment, the importance 
of IL17 in the development and promotion of papilloma in the skin was shown. This 
effect occurred via activation of STAT3 by IL-6 which was induced by IL-17.291 However, 
many other studies showed anti-tumor activity of Th17.  Muranski et al. showed that 
polarized IL-17 secreting CD4+ cells have a better anti-tumor function than Th1 cells.  
They noted that Th17 cells were able to produce IFN-γ which is known to have a potent 
anti-tumor function.292 This also contributed to the concept that different types of Th 
cells exhibit functional plasticity.278,293  In another study, it was demonstrated that Th17 
were able to stimulate tumor rejection through activation of CD8+ T cells.  Ovalbumin 
(OVA)-specific Th17 cells acquired peptide/MHC1 and secreted IL-2, which activated 
anti-tumor functions of CD8+ CTL but not thru IL-17.  This study provides the base idea 
to design preventive Th17-based anti-tumor therapy. 294  
Other findings strengthen the idea of a possible plasticity or inter-phenotype 
change within the T helper cells populations.  In another study, it was shown that human 
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Th17 can secrete IL-17 and IFN-γ and express ROR-γt and T-bet (Th17 and Th1, 
respectively) within the gut of Crohn’s disease (CD) patients.   Expression of IFN-γ by 
differentiated Th17 was attributed to the presence of IL-12.295  These findings could be 
expected since IL-23 is the cytokine necessary for Th17 maintenance and belongs to 
the IL-12 family of cytokines.296  Further this same study revealed that the chemokine 
receptor CCR6 was expressed in Th17 cells.295  CCR6 was up-regulated in memory 
CD4+ T cells and B cells but not in naïve CD4+ T cells or Th2 cells.297,298 Its ligand, 
CCL20, have being shown to selectively attract memory T cells.298  The selective 
expression of CCR6 in Th17 and Th1/Th17 population suggested that these cells may 
remain activated long time after its activation and therefore, could be attracted to the 
site of inflammation.   
Th17 cells can also acquire characteristics of T regulatory cells (Tregs).  Inverse 
correlation of the number of Th17 and Tregs was found in tumor 
microenvironment.200,299 This relationship became evident when it was discovered that 
these cells shared requirement of TGF-β in the differentiation from naïve CD4+ T cells 
into anti-inflammatory Tregs and into pro-inflammatory Th17 phenotype.300  As 
discussed above the development of Th17 apart of TGFβ, strictly requires the presence 
of a pro-inflammatory cytokines, like IL-6, derived from activated DCs, or other cells 
present in the inflammatory environment.  Therefore, in an environment deprived of pro-
inflammatory cytokines most likely naïve CD4+ T cells have potential to differentiate into 
Tregs.301  Differentiation of functional Tregs requires the expression of  Forkhead Box 
P3 (FoxP3) transcription factor which is necessary for its development and 
maintenance.302  Interestingly, uncommitted T cells begin to express both ROR-γt and 
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FoxP3 in the presence of TGFβ alone but failed to express IL-17. Eventually it was 
noted that ROR-γt expression was diminishing and Tregs development was more 
apparent.  Likewise, a transient co-expression of ROR-γt and FoxP3 was seen early 
differentiation of Th17, in which FoxP3 was gradually down-regulated.303,304  Moreover, 
in a human study it was shown that different subset of myeloid cells isolated from 
peripheral blood can induce differentiation of Tregs or Th17 in a TGF-β-dependent 
fashion. MDSCs, defined with the surface markers CD14+HLA-DRlow/- , and monocytes, 
with surface markers CD14+HLA-DR+, isolated from peripheral blood were able to 
differentiate Tregs and Th17 respectively.305 These two myeloid cell populations 
express TGF-β, which is an essential requirement for Tregs and Th17 differentiation. 
These particular MDSCs did not express pro-inflammatory cytokines, like IL-6, 
necessary for Th17 generation and therefore contributed to FoxP3 up-regulation and 
Tregs development. On the other hand monocytes could secrete the inflammatory 
cytokines and induce differentiation of Th17 by upregulating of ROR-c. These findings 
suggest that the environmental factors can determine the final effector phenotype of T 
cell population thus regulating the outcome of the disease. More importantly, this work 
further demonstrated that the MDSCs were able to differentiate Tregs from Th17 cells 
via a retinoic acid (RA)-dependant mechanism. It has been shown that RA, a metabolite 
of vitamin A, can induce Tregs’ differentiation by suppressing IL-6 induction of Th17 
cells.  Upon addition of RA agonists to the co-culture of differentiated Th17 and MDSC, 
MDSCs enhanced the conversion of Th17 into FoxP3-expressing Tregs cells. Further, 
blocking the retinoic acid receptor or TGFβ receptor demonstrated a reduction of the 
conversion of Th17 into T regulatory cells.305  This is an important observation because 
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it can partially explain the mechanisms underlying the pro-inflammatory versus 
suppressive immunity within the tumor environment.  
 
T regulatory cells (Tregs). Tregs are developmentally and functionally different 
T cell subpopulation that contribute to self-tolerance.306 Although these cells are being 
identified by expression of CD25 surface marker this marker doesn’t discriminate 
among other effector T cells and suppressive Tregs.   FoxP3 has been identified as the 
principal transcription factor that allows the development of suppressive Tregs.307,308 
Two subpopulations of CD4+ Tregs were identified: thymus-derived natural occurring 
CD4+CD25+FoxP3+ Tregs (nTregs), and those that can be induced ex-vivo from CD25- 
precursors in peripheral lymphoid organs (iTregs).  These two subpopulations can be 
found within the same environment and contribute to immune suppression.309,310 The 
main function of these cells is to execute its suppressive activity against CD4+CD25- T 
cells, CD8+ T cells, B cells and Natural Killer (NK) cells in a cell to cell contact and/or 
secreting immunosuppressive cytokines such as IL-10 and TGF-β. This suppressive 
activity allows down-regulation of excessive immune responses and maintains T cell 
tolerance to self-antigens.311,312 Expansion of Tregs in cancer favors tumor development 
and progression through the inhibition of anti-cancer responses.  As mentioned above, 
TGF-β is the cytokine necessary for Tregs cell differentiation from naïve CD4+ T cells.  
Generally, TGF-β has been identified as an immunosuppressive cytokines but this 
cytokine has pleiotropic functions in T cell responses.313 TGF-β supports the 
maintenance of FoxP3 expression, the suppressive function and homeostasis in 
peripheral Tregs.314 TGF-β also has been implicated in the role of retinoic acid (RA) in 
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the Tregs development.  RA can interfere with inhibitory cytokines that prevent 
development of Tregs and further can enhance expression of FoxP3 transcription 
factor.315,316 
The increased presence of Tregs in the tumor environment often correlates with 
poor prognosis.  Moreover, detection of a high frequency of Tregs can prevent 
successful anti-tumor therapies in cancer patients.317 Animal model experiments also 
corroborate the participation of Tregs in tumor progression.  Depletion of these cells is 
associated with tumor rejection, which is probably can be explained by a change in 
cytokine availability. Tumor cells and tumor environment are capable of inducing DC to 
secrete TGF-β thus promoting Tregs’ differentiation from peripheral naïve CD4+ 
cells.137,318  The expression of chemokines and chemokine receptors can contribute of 
recruitment of Tregs to the tumor environment. Activated Tregs can express CCR4 and 
therefore can be  recruited to the tumor environment by tumor cells and macrophages 
that express CCL22,  the ligand of CCR4.319  The hypoxic environment found in ovarian 
tumors secretes CCL28 which in turn attract Tregs via the engagement of CCL28 and 
its receptor CCR10 that is present in these regulatory cells.320 Once the Tregs reach the 
tumor environment, they contribute to immune attack suppression and angiogenesis by 
in the tumor environment, Tregs contribute to immune suppression by secreting TGFβ, 
IL-10 and IL-35.319,321  
 
Chemokines and Inflammation  
It has been demonstrated that chemokines can promote carcinogenesis by 
setting the condition for the onset and progression of inflammation.322 Although 
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chemokines can have biological purposes, which includes regulation of hematopoiesis, 
fibrosis and angiogenesis, these chemoattractants can operate as a signal to guide 
cellular migration which coordinates leukocyte recruitment in physiological and 
pathological conditions.323,324  Chemokines can be divided into two groups depending 
on their function: “inflammatory” chemokines and “homeostatic” chemokines. 
Inflammatory chemokines mediate trafficking of leukocytes to the inflammations site and 
help develop strong immune responses. Homeostatic chemokines are constitutively 
expressed, involved in lymphocyte and DC trafficking, and can recruits cells to the 
hematopoietic organs.325 Inflammatory chemokines mediate the interaction among 
leukocytes, lymphocytes, tumor cells, stromal cells with each other resulting in tumor 
growth and dissemination.326,327 The first modification of the resident cells within the 
chronic environment leads to the secretion of non-specific pro-inflammatory cytokines, 
such as IL-1α/β, IL-6, TNF-α and IFN-γ and these molecules subsequently can induce 
the secretion of other pro-inflammatory chemokines. These chemokines and cytokines 
can act in a paracrine and autocrine fashion helping to magnify of inflammatory 
responses.328 All these events contribute to the persistence of inflammation which 
promotes the conversion of normal cells to pre-neoplastic cells.329   
Chemokines are small peptides (8-17 kD) secreted by cells to attract other cells 
to the microenvironment. Chemokines comprise the largest family of cytokines. Is been 
classified into CC, CXC, C, and CX3C depending on their relative positions of 
conserved cysteine residues in the mature sequence of the protein.  Chemokines binds 
to its receptor, a family of 7 transmembrane domain G-protein coupled proteins.  There 
are 4 families of chemokines receptors: CC, CXC, CX3C and X3.322 Two steps have 
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been proposed to describe the action and activation of chemokines and its receptors.  
The first step is the recognition of the chemokine with its specific receptor.  The second 
step relies on the activated receptor.330 Chemokine receptor undergoes a 
conformational change upon chemokine binding, which causes an exchange of GDP to 
GTP in the α-unit of the G protein. This results in the activation of a downstream 
signaling cascade, which in part leads to the expression of integrins allowing attachment 
of the leukocytes to the endothelial surface and subsequent extravasion.331  The 
activation of the receptor and up-regulation of integrin molecules on the cell surface are 
needed for complete activation of leukocytes, enhancement of phagocytosis, 
superoxide production, granules release and microbicidal activity.323   It is important to 
note that many chemokines can bind to more than one receptor with high affinity, and 
similarly, that some chemokine receptors don’t discriminate with different chemokines. 
This promiscuity allows for the development of a large array of coordinated 
responses.332  Recent studies have identified chemokines and chemokine receptors that 
elicit and sustain inflammatory events in the environment that could evolve into 
cancer.322  Consequences of the engagement of chemokines and its respective 
receptors are activation and/or inhibition of pathways within targeted cells that could 
accelerate the process of carcinogenesis.333 Mononuclear cells can be attracted by 
chemokines to the inflammation site.334  Anti-inflammatory cytokines, such as IL-10, can 
induce up-regulation of pro-inflammatory chemokine receptors CCR2, CCR5 and CCR1 
in monocytes.335 On the contrary, the same chemokines receptors were down-regulated 
in the presence of a pro-inflammatory environment.336 This effect might provide an 
inhibitory signal to prevent excessive macrophage recruitment at the sites of 
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inflammation and tissue damage.337  The involvement of chemokines in the recruitment 
of immature myeloid cells to the tumor environment depends on the phenotype of the 
myeloid cells and the tumor model. From the four known families of chemokines, CC 
family is the predominant family in the infiltration by TAMs and T cells.338.  In early 
stages of cancer development, IMCs expressing CCR1 are recruited by CCL9, which is 
produced in the tumor epithelium.339 More specifically, it has been demonstrated that M-
MDSC are recruited to melanoma tumor environment through interaction of CCL2 with 
its receptors CCR2, CCR4 and CCR5.340,341 Other groups reported the participation of 
different chemokines in the migration of MDSC to the tumor site.  In ovarian and gastric 
cancer it has been shown the participation of CXCL12 and CXCL8 (also known as IL-
8).342,343  Animal models also showed the chemokine-induced MDSC migration towards 
the tumors.  Sawanobori et al. demonstrated that M-MDSCs were attracted to the tumor 
site by CCL2/CCR2 interaction; meanwhile, PMN-MDSCs were attracted by CXCR2 
ligands secreted by tumor cells.340   These studies supported the active and important 
role of chemokines in IMC/MDSC destiny and their contribution to cancer 
progression.128,340,344  Chemokines can expand its influence to T cells lineages.345 
Tumor infiltrated CD8+ cells that express CCR7 are positive prognosis markers in colon 
cancer patients. Once CCR7 is engaged to its ligands, CCL21 or CCL19 can mobilize 
CD8+ cells to lymph nodes or to the tumor environment and executes its cytotoxic 
response.346  In a study of breast cancer, Curiel et al. have shown that Tregs expressing 
CCR4 are attracted to the tumor environment by CCL22 secreted by tumor associated 
macrophages and tumor cells. 347 
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It is clear that the cells and molecular components that induce chronic 
inflammation influence tumor development.  Knowledge and understanding of these 
complicated processes driving the inflammation and tumor development could lead to 
the development of new therapies to counteract the malignant progression.  
 
Macrophage Inflammation Protein-1 beta (MIP-1β) / CCL4. The first 
characterization of this chemoattractant protein was made in the late 80’s when murine 
macrophages were stimulated with LPS which induced the secretion of multiple factors 
including a new and unidentified monokine.  This heparin-binding protein attracted PMN 
when was injected to mice and rabbits, where it could act as an endogenous pyrogen 
and induce granulocyte-macrophage colony formation.348 In in-vitro studies showed that 
CCL4 attract PMN and induce superoxide production in human PMN 348,349  Because of 
these inflammatory properties, this protein was named as macrophage inflammatory 
protein (MIP).349  Further, SDS-PAGE assay was able to identified two distinct protein 
doublets that were highly related, MIP-1α and MIP-1β with 68% homology.350 MIP-1β or 
chemokine (CC-motiff) ligand-4 (CCL4) is the member of the MIP family that include 
MIP-1α (CCL3), MIP-1δ (CCL9/10) and MIP-1γ (CCL15).351  These are 8-10 KDa 
proteins.322 In mice and humans, CCL4 is encoded by the genes consisting of three 
exons and two introns positioned in chromosome 17.351  This chemokine is synthesized 
as an immature precursor of 92 aminoacids.  After subsequent cleavage in hydrophobic 
specific aminoacids by peptidases, the mature protein consists of 69-70 aminoacids. 350 
Generally, CCL4 and CCL3 production can be induced by different pro-inflammatory 
cytokines/agents, such as LPS, IFN-γ, IL-1β, TNF-α, viruses, etc. Anti-inflammatory 
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cytokines such as IL-4 and IL-10 can down-regulate its expression.  Upon stimulation 
with LPS or IL-7 human monocytes can secrete significant amounts of CCL4. In addition 
lymphocytes are capable of secreting CCL4 upon antigen binding.352  CCL4, secreted 
by PMN in the skin, is found to be an important mediator of macrophages migration in a 
murine model of cutaneous granuloma formation.353  In parasite infection, CCL4 can 
induce the secretion of IL-12 by resident DCs, which contribute to Th1 infiltration which 
facilitate the clearance of the worm by cytokine effect.354  Recently, in a model of 
tumorigenesis of prostate cancer, it was demonstrated that CCL4 participates as a 
mediator of macrophages to promote malignant differentiation of immortalized prostate 
epithelial cells.355 
The recognized receptor for CCL4 is CCR5, although in HIV models a modified 
version of CCL4 can signal through CCR1 and CCR2b.350,356 This receptor is expressed 
mainly in subpopulation of lymphocytes and in monocytes/macrophages.350,357  
Signaling through any of these receptors induces the internal rearrangement of the G 
proteins.  This new conformation of G proteins results in the activation of 
phosphoinositide 3-kinase (PI3K) pathway and phospholipase C signaling pathway 
which permits the influx of Ca2+ and activation of protein kinase C (PKC).351    Soon 
after its discovery, CCR5 is recognized as co-receptor that facilitates the entry of HIV-1 
virus in CD4 T helper cells.  The gp120 glycoprotein of the HIV binds to CD4 protein in 
the target cells, which cause a conformational change in gp120.  This rearrangement 
allows the entry of the virus.358 CCR5 has been implicated as a possible mechanism of 
cancer progression.  Tan et al. demonstrated that Tregs participated in early 
development of pancreatic cancer via CCR5 expression.  Administration of small 
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molecules CCR5 antagonist was able to reduce infiltration of Tregs to the tumor site and 
slow down the tumor growth in mice.359   
For many years different chemokines have been implicated in the migration of 
leukocytes to the site of injury and infections.360 Therefore, it is conceivable that MIPs 
family can help orchestrate pathogenesis in many inflammatory conditions and 
diseases, including cancer.351,360 However, there is limited data demonstrating that 
cancer cells can also secrete MIPs, particularly CCL4.  In an in-vitro experiment, Burger 
et al. demonstrated that Chronic Lymphocytic Leukemia (CLL) cells co-culture with 
monocyte-derived nurse-like cells (NLC) express high amounts of CCL3 and CCL4.  
The induction of CCL3 and CCL4 was a result of the activation of CCL B cell receptor in 
response to antigen presented by NLC.  Secretion of CCL4 and CCL3 support 
interaction of CCL with T cells and might explain maintenance of tumor 
microenvironment and CCL diffusion to other organs.361 Erreni et al. have identified 
highly expressed chemokines and chemokines receptors in tumor tissues from human 
colorectal cancer. Among the chemokines they found that CCL4 andCCL3, were highly 
expressed in the tumor samples compared to normal tissue. It is known that these 
chemokine are ligands for CCR1 and CCR5-expressing monocytes/macrophages but 
they couldn’t decipher if these infiltrated myeloid cells are pro-tumor or anti-tumor.  
Moreover, they couldn’t associate the, the up-regulation of these chemokines with the 
stage of the tumor.362 
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Myeloid cells induce T cell migration towards the inflammatory site 
It is well documented that TAMs and MDSC influence tumor development.363,364 
The migration of these myeloid cells into the neoplastic tissue can aid in the stroma 
remodeling, angiogenesis, and the influx of lymphocytes that contributes to cancer 
formation.  Besides the well-studied suppression mechanisms against CD8+ CTLs  
these myeloid cell populations secrete other inflammatory factors, which contribute to 
the persistence the inflammation.137 It has been reported that pro-inflammatory 
cytokines, such as IL-6 and IL-1β, not only contribute to myeloid cells recruitment and 
proliferation but also can help the infiltration of lymphocytes into the tumor 
microenvironment.365  As discussed above,  one function of pro-inflammatory cytokine 
IL-6 is to promote the differentiation of naïve CD4 lymphocytes into the pro-
inflammatory phenotype, Th17, in the presence of TGFβ.271  Th17 can counteract the 
tumor suppressive IFNγ-secreting Th1 in the tumor environment.366 Several studies 
have shown that among TILs population, Th17 found at high percentage in different 
types of cancer.299,367,368 Upon arrival to the neoplastic tissue effector Th17 can secrete 
pro-inflammatory cytokines, such as  IL-17, IL-1β, IL-23, which generally favor tumor 
growth but also can limit tissue damage depending on the site of the tissue site .369   
Chemokines are the primary molecules that drive the infiltration of myeloid cells 
into the tumor environment.98,344.  Further the myeloid cells that are present in the tumor 
environment can also secrete chemoattractants to induce the infiltration of 
lymphocytes.370 CCL17, CCL22, CCL24 can support the immunosuppressive 
environment by inducing migration of Tregs to the inflammatory site.139,371 Further, IL-4 
secreted by Th2 can attenuate CD8+ T cells cytotoxic immunity and induce the 
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development of immunosuppressive macrophages.136,226 Within the tumor 
microenvironment, TGF-β secretion is not limited to macrophages only.  MDSCs are 
also able to produce this cytokine which contribute to their immunosuppressive 
function.372  In addition, TGF-β produced by MDSCs can favor the differentiation and 
infiltration of naïve CD4+ T cells to T regulatory cells.  Within the emerging cancerous 
tissue, chemokine productions by MDSCs and TAMs also have been implicated as 
immunosuppression mechanisms within the tumor site. In the Lewis Lung Carcinoma 
(LLC) model, CCL22 secreted by these myeloid cells and not by tumor cells can 
promote the infiltration of CCR4 expressing Tregs which collaborate into promoting the 
suppressive environment thus favoring cancer development.  Interestingly, in this model 
CCL22 was produced by MDSCs and not by tumor cells. 373  
Chemokines also play an important role in the tumor development. Chronic 
inflammation is characterized by the persistent infiltration of leukocytes. Oo et al. 
reported that during chronic liver inflammation DCs from the affected area secretes the 
CCR4 ligands, CCL22 and CCL7, which recruits Tregs thus showing to immune 
suppression within the environment.374   In another study, Yurchenko et al. reported that 
infection with parasite Leishmani become persistent with the infiltration of Tregs in 
dermal sites. Upon infection with the parasite CCR5 ligands CCL3, CCL4 and CCL5 are 
secreted possibly by DC, infected macrophages, or effector T cells which enable CCR5+ 
Tregs to migrate to the site of infection. Further, they found that in CCR5KO mice were 
resistant to the parasite infection which correlates with Th1 responses seen on the site 
of infection.375  Himmel et al. have shown that it was possible that activated human 
Tregs could secrete chemokines, specifically CXCL8, to improve its immunosuppressive 
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activity.  They also showed that other chemokines, such as CCL3, CCL4, were secreted 
upon stimulation with CD3 and CD28 antibodies and that these chemokine-secreted 
Tregs were able to recruit PMN.376 
It is important to note that due to the nature of the process of inflammation and 
eventual carcinogenesis the expression of chemokines within this environment attracted 
mainly effector or memory T cells.377  These activated lymphocytes, mainly CD4+ T 
cells, have high expression of chemokine receptors and respond to respective ligands 
by migrating to the inflammatory site.378   
All these studies strongly suggest the importance of chemokines and chemokine 
receptors within the inflammatory environment and its contribution to the infiltration of 
leukocytes.  Understanding of the mechanisms of their recruitment may help to develop 
novel therapies that can inhibit the possible development of cancer.   
 
Tumor cells need Inflammation for survival and metastasis  
Cancer cells can elicit the inflammation to support the proliferation and survival of 
malignant cells. The stimulus within chronic inflammation can promote cancer survival, 
new vessel formation, and metastases. The formation of metastasis can be supported 
by inflammatory environment, which can suppress immune response and interfere with 
immuno- and chemotherapeutic drugs.379 380 One of the most important elements of 
cancer metastasis is the ability to move to distant organs and/or tissues through the 
blood circulation, lymphatic vessels or serosa surfaces.381  Recently, it was proposed 
that the tumor cells within a tissue are not a uniform population. Tumors contain 
population of cells that may contribute to tumor aggressiveness. Cancer Stem Cells 
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(CSCs) are tumor cells able to derive new tumor cells when implanted in vivo. Another 
important trait of CSC is the ability to evade apoptosis, distinct mobility, and 
invasiveness.382 It was suggested that metastatic cancer cells undergoing epithelial-
mesenchymal transition (EMT), enabling them to invade distant tissues by reducing 
signatures adhesion molecules, such as E-cadherin. EMT in cancer cells is supported 
by the tumor microenvironment characterized by inflammatory cells and 
molecules.383,384  
The inflammatory cells provide additional factors that can potentiate the tumor 
cells to become invasive.  For example, TAMs (the cells that predominate in the tumor 
environment) can secrete a wide variety of growth factors and cytokines that aid in the 
motility, growth and invasiveness of tumor cells.  In addition, TAMs can secrete 
proteinases that degrade the basal membrane creating a channel for tumor invasion.  
TNF-α secreted by the TAMs dramatically enhances the invasiveness of tumor.379,385  
Further, metalloproteinases (MMP) secreted by TAMs can also contribute in tumor 
progression.  In a lung cancer model, the functional importance of MMP-9 secreted in 
the neoplastic tissue was confirmed. The MMP-9 found in the lung was prior localized in 
distant tumor prior metastasis.   A decrease in lung metastasis was found in MMP-9 
deficient host suggesting the functional importance in the pre-metastasis sites. 386 
Recent studies have shown a close correlation between the level of MDSCs and 
cancer stage, metastatic tumor burden and chemotherapy responses. Several studies 
suggest two hypothesis in which MDSCs participate in tumor invasion and metastasis. 
387 The first one is that MDSCs can secrete factors, such as MMP and chemokines that 
can prepare the environment for tumor progression and metastasis.387-389 The second 
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one is that tumor cells can apparently can usurp or take over MDSCs machinery and 
use it for self-maintenance enabling them to metastasize.390,391  Further, S100A8 and 
S100A9, the proteins that are up-regulated in MDSCs, have been shown to contribute to 
tumor invasiveness.392 Within the established tumor environment these proteins 
promote the phosphorylation of MAPK and activation of NF-κB which allows migration of 
the neoplastic clone.393,394 Addition of S100A8/A9 into B16 melanoma cells in which 
activates matrix metalloproteinases that is associated with tumor metastasis.395   
Moreover, in early 2000s, Taguchi et al. reported that the blocking RAGE, the receptor 
for S100A9 protein, can decrease metastasis in vivo, as well cell growth and 
migration.396 
High levels of these proteins are correlated to poor prognosis in cancer patients. 
397  The fusion of bone marrow derived cells (BMDC) and tumor cells is another 
described phenomenon that contributes in tumor metastasis.  These hybrids have been 
detected in several animal models and in human cancer. Molecular studies suggest that 
these hybrids up-regulate genes associate to metastatic cancer cells and genes 
associated with migratory macrophages and other BMDC. 391 
CXCR4 is the chemokine receptor strongly associated in metastatic cancer.322,398 
The chemokine ligand that binds to CXCR4 is CXCL12 also known as stromal cell 
derived factor 1 (SDF1).399 This chemokine/chemokine receptor complex is related to 
trafficking of HSC andvascularization, as well as to heart and brain development. 
CXCL12 is considered a hematopoietic chemokine and its principal function is to 
regulate hematopoietic cell trafficking and formation of secondary lymphoid organs.  
However, CXCL12  is also associated with tissue injuries such as heart infarction, liver 
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toxicity, and adverse consequences chemotherapy treatment.400 There is abundant 
evidence suggesting that chemokines can influence the traveling of primary tumors to a 
secondary lymphoid location by up-regulating genes related to cell survival, cell 
adhesion and other genes transcription that coordinate trafficking of cells.401 The 
overexpression of CXCR4 has been observed in more than 20 different types of cancer, 
including melanoma, ovarian, glioma and pancreatic.402 Interestingly, CXCR4 is highly 
associated with CSC and has been implicated in survival and metastasis of  
gliobastoma tumor cells and pancreas tumor cells.98 CXCR4 is expressed in a variety of 
cells BM derived  cells  including, early T and B lymphocytes, CD34+ cells, monocytes, 
granulocytes and endothelial progenitor cells among others.  These CXCR4+ cells 
exhibit pro-angiogenic properties which include infiltration of CXCL12 secreting cells for 
neovascularization and support of tumor growth.400,403  
As we discussed previously, early stages of cancer, characterized by 
inflammation, have many different cells that interact with each other and confabulate to 
create a neoplastic environment. It has become well known that myeloid cells, 
specifically MDSCs, participate in chronic inflammation that leads to tumor formation as 
well as in other inflammatory diseases. This project intends to identify the specific role 
of MDSC in tumor development and possible mechanism of their involvement. 
 
 
Hypothesis 
 
 
Immature myeloid cells accumulated during chronic inflammation and promote 
tumor development.  
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Aim #1. To investigate the role of immature myeloid cells and MDSC in skin 
tumor development.   
Aim #2. To determine the role of MDSC and immature myeloid cells in the 
development of lung cancer.  
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CHAPTER 2.  IMMATURE MYELOID CELLS FOSTER 
TUMOR DEVELOPMENT VIA RECRUITMENT OF CD4+ T CELLS 
 
Rationale  
There is now ample evidence of abnormalities in the myeloid compartment in 
cancer, which manifests in inhibition of differentiation of dendritic cells (DC), polarization 
of macrophages (MΦ) towards M2 functional state, and dramatic expansion of myeloid-
derived suppressor cells (MDSC).136  MDSCs represent a heterogeneous population of 
pathologically activated myeloid cells that includes precursors of neutrophils, MΦ, DCs 
cells, and cells on earlier stages of myeloid cell differentiation.147,151  In mice, these cells 
are defined as Gr-1+CD11b+ cells with the recognition of polymorphonuclear (PMN-
MDSC) and mononuclear (M-MDSC) subsets based on the expression of Ly6C and 
Ly6G markers.156,178,180,404 PMN-MDSC largely consists of pathologically activated 
immature neutrophils, whereas M-MDSC are pathologically activated monocytes.159 
MDSCs are characterized by a potent immune suppressive activity and the ability to 
promote tumor angiogenesis, tumor cell invasion, and metastases.151,405  In tumor-free 
mice, cells with the same phenotype represent immature myeloid cells (IMC) as well as 
neutrophils and monocytes lacking immune suppressive activity. Expansion of MDSC is 
considered a consequence of tumor progression. However, in recent years, it has 
become clear that the cells with phenotypes and functions attributed to MDSC are  
readily detectable at different conditions associated with chronic inflammation, sepsis,  
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transplantation, etc. not directly linked to cancer.406  
Inflammation is developed in response to foreign agents or injuries and is an 
important part of the healing process. However, if inflammation is not resolved and 
becomes chronic, it may become an important contributing factor in the development of 
cancer.5  Myeloid cells together with lymphocytes are the main components of 
inflammation.  The exact nature of myeloid cells that trigger initial tumor development as 
well as the nature of their interaction with lymphocytes is not clear. Since cells with 
MDSC phenotype are frequently associated with chronic inflammation, we were 
interested in establishing their involvement in initial steps of tumor development. This 
may have potential therapeutic implication since strategies to target MDSC are currently 
being developed for clinical purposes.136   
In order to formally address this question, one needs to set up a condition where 
immature myeloid cells (IMC) accumulate in tissues without confounding effects of 
various pathologic factors. To achieve this goal we used experimental models with 
regulated expression of S100A9 protein, the member of S100 family of Ca2+ binding 
proteins.167 Expression of S100A9 together with its dimerization partner S100A8 is 
found predominantly in cells of the myeloid lineage.  Promyelocytes differentiating to 
myelocytes/granulocytes increase expression of S100A9, whereas differentiation of MΦ 
and DCs is associated with loss of S100A9/A8 expression.   Cells of the lymphocytic 
lineage do not express these proteins. We and others have previously found that 
accumulation of MDSC and inhibition of DC differentiation in cancer were closely 
correlated with upregulation of S100A8/A9.167 The expansion of MDSC was significantly 
reduced in S100A9 deficient tumor-bearing mice and mice treated with complete 
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Freund’s adjuvant (CFA).167 Furthermore, this was consistent with more recent report 
that DCs derived from S100A9 deficient mice induced stronger response of allogeneic T 
cells.  On the other hand, overexpression of S100A9 in transgenic mice resulted in 
inhibited DCs and MΦ differentiation.167  These results suggested that manipulation of 
S100A9 in myeloid cells could facilitate the accumulation of IMC and thus open the 
opportunity to directly test the role of these cells in tumor development.    
 
Results 
The role of immature myeloid cells in tumor development.  Tumor 
development was studied in two models of skin carcinogenesis. Tg.AC mice on FVB/N 
background express the mutant v-h-ras transgene under the zeta-globin promoter. 
When treated topically with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate 
(TPA), Tg.AC mice develop multiple papillomas, some of which progress to a malignant 
stage.407  In C57BL/6 mice, skin tumor formation was induced by a single application of 
the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) followed by 12-week topical 
treatment with TPA. To test the role of IMC in tumor development we used transgenic 
mice expressing the S100A9 protein in hematopoetic cells (S100A9Tg mice).167 These 
mice on FVB/N background had no detectable abnormalities during the first 4-5 months 
of life. Compared to wild-type (WT) mice, S100A9Tg mice expressed higher amounts of 
S100A9 protein in bone marrow (BM), spleen, lymph nodes (LN), and lung, but not in 
skin or liver (Figure 4A). S100A9 could be induced in keratinocytes under inflammatory 
conditions. However, topical treatment of WT mice with TPA for 4 weeks did not result 
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in detectable levels of S100A9 in skin. In contrast, the same treatment of S100A9Tg 
mice caused a substantial increase in the amount of the protein (Figure 4B).  
 
 
Figure 4.  Expression of S100A9 protein in different organs of WT and S100A9tg 
mice: (A) Basal amount of S100A9 protein expressed in different organs of WT and 
S100A9tg mice. (B)  Expression of S100A9 protein on skin of S100A9tg and WT mice 
after treating with TPA or vehicle (acetone). Each lane represents one mouse.  Shown 
is typical Western Blot with 30ug protein total.  
 
 
We assessed the presence of myeloid cells in skin by immunohistochemistry. 
While treatment of WT mice with TPA resulted in a small increase in the number of Gr-
1+ cells, in S100A9Tg mice these cells increased ~3-fold (p<0.01) (Figure 5A, B). 
Evaluation of cells derived from skin sample digests by flow cytometry revealed that all 
the Gr-1+ cells also expressed CD11b. The proportion of Ly6ChiLy6G- monocytic cells 
among CD11b+ cells in TPA-treated skin was the same in WT and S100A9Tg mice, 
whereas the proportion of Ly6CloLy6G+ granulocytic cells was dramatically higher in 
S100A9Tg than in WT mice (Figure 5C). No differences in the numbers of  F4/80+ MΦ 
between WT and S100A9Tg skin were found regardless of treatment (Figure 5D), 
whereas the number of CD11c+ cells was significantly lower in both acetone and TPA 
treated S100A9Tg skin than in WT skin (Figure 5E). 
B A 
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Figure 5. The presence of myeloid cells in the skin of WT and S100A9tg mice: (A) 
Representative picture of Gr1 staining in immunohistochemistry assay. Scale 
bar=100um. (B)  Graph of Gr1+ cells per mm2 of skin tissue. Each group combined 4 
mice. Mean and SD is shown (*p<0.05, **p<0.01).  (C) Phenotypic characterization of 
myeloid cells on TPA-treated skin.  Flow cytometry plots are shown (left), numbers 
represents gated cells. Bar graphs represent the distribution of cells (right), *p<0.05 (D) 
Graph of F480+ and (E) CD11c+ cells of TPA-treated mice.  Each group included 4 
mice. Mean and SD is shown, (*p<0.05, **p<0.01) 
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We asked whether dramatic increase in the presence of granulocytic IMC in the 
skin of S100A9Tg mice was the result of expansion of these cells. There was a slight 
increase in the presence of IMC in BM of TPA treated S100A9Tg versus WT mice but 
the ratio between granulocytic and monocytic subsets of IMC was the same (Figure 6A, 
B). The presence of MΦ in BM of S100A9Tg mice was slightly lower than in WT mice 
(Figure 6C). These data indicate that consistent with previous observation167 
overexpression of S100A9 in myeloid progenitors did not cause expansion of myeloid 
cell population but rather inhibited their differentiation. Topical application of TPA in 
S100A9Tg mice caused a substantial accumulation of IMC with granulocytic phenotype, 
whereas the presence of MΦ and DCs was either unchanged or decreased.  
To study skin carcinogenesis, the S100A9Tg mice were crossed with 
homozygous Tg.AC mice, and hemizygous monotransgenic (Tg.AC) and bitransgenic 
(S100A9:Tg.AC) littermates were topically treated twice weekly for 6 weeks with the 
tumor promoter TPA. Papillomas developed much faster and at significantly (p<0.001) 
higher numbers in bitransgenic mice expressing S100A9Tg than in monotransgenic 
mice (Figure 7A). To clarify the role of infiltrating BM derived cells in increased 
tumorigenesis in S100A9Tg mice, lethally irradiated Tg.AC mice were reconstituted with 
BM from WT or S100A9Tg mice and papilloma formation similarly evaluated after TPA 
treatment. Recipients of S100ATg BM developed significantly (p<0.05) more papillomas 
than recipients of BM from WT mice (Figure 7B) demonstrating that upregulation of 
S100A9 in BM-derived hematopoietic cells was responsible for increased tumor 
formation. To confirm specific role of IMC in tumor development, Gr-1+ cells were 
depleted in Tg.AC mice with Gr-1 antibody during the first three weeks of TPA 
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treatment. This treatment significantly (p<0.05) reduced papilloma formation (Figure 
7C).  
 
To better ascertain the possible role of IMC in tumor development we also used 
mice with targeted deletion of S100A9 (S100A9KO mice, C57BL/6 background).194 In 
contrast to FVB/N mice, untreated WT C57BL/6 mice had traces of S100A9 protein in 
the skin, which was increased after 4 weeks of TPA treatment (Figure 8A). S100A9KO 
mice had no detectable S100A9 protein in the skin (Figure 8A). Treatment of C57BL/6 
mice with TPA greatly increased the number of Gr-1+ myeloid cells in the skin, whereas 
in S100A9KO mice, this increase was very modest and lower than in WT mice (Figure. 
8B). In contrast to S100A9Tg mice, S100A9KO mice developed significantly (p<0.01) 
fewer skin tumors than their WT C57BL/6 counterparts after treatment with both DMBA 
and TPA (Figure 8C). Mice reconstituted with BM from S100A9KO mice had 
significantly (p<0.01) less number of lesions than mice reconstituted with WT BM 
(Figure 8D), confirming the critical role of BM derived cells in modulating skin 
tumorigenesis. Collectively, these data demonstrate that development of skin tumors 
directly depended on the accumulation of granulocytic IMC in the skin. Next we 
investigated the mechanism(s) by which IMC mediated tumor promotion. 
 
Accumulation of IMC in skin did not result in immune suppression.  We 
tested the hypothesis that IMC accumulated in TPA-treated S100A9Tg skin had 
immune suppressive activity and thus could be classified as MDSC. Since isolation of  
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Figure 6. Myeloid cells accumulation in the bone marrow after TPA treatment of 
mice skin:  Distribution (left) and absolute number (right) of (A) Gr1+CD11b+ cell (B) 
Ly6C/Ly6G ratio within the population of CD11b+ cells and (C) F480+CD11b+ cells in 
bone marrow of TPA treated mice. Each group included 4 mice. Mean and SD are 
shown. * p<0.05 between groups 
A 
C 
Gr1+CD11b+ cells  
     Ly6G+/Ly6C+ cells     B 
F480+cells   
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Figure 7. IMC exacerbate  papilloma formation : (A) Papilloma formation on skin of 
TgAC and S100A9tgxTgAC double transgenic mice after TPA treatment for 6 weeks.  
Mean and SD of papilloma formation per mouse is shown. Seven mice per group 
P=0.0071.  (B) Papilloma development in lethally irradiated Tg.AC mice that received 
BM from S100A9Tg or WT (control) mice. TPA treatment started three weeks after the 
BM transfer. Each group included 4 mice (p=0.035). (C) Papilloma development on 
TgAC treated with anti-Gr1 antibody as denoted in the graph.  Each group has 5 mice. 
Shown is the mean and SD of the number of papillomas per mouse (p<0.001).  
  
A B 
C 
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Figure 8. Deficiency of IMC resulted in less papilloma formation:  
(A) Expression of S100A9 protein in WT C57BL/6 and S100A9KO mice after TPA or 
acetone (vehicle) treatment.  Each lane represent 1 mouse.  Positive control (PC) are 
splenocytes from tumor-bearing mice.  (B) The number of Gr-1+ cells in skin of C57BL/6 
mice evaluated by IHC. Mice were treated with TPA or acetone for 4 weeks. Each group 
included 4 mice. **p<0.001. In all panels mean and SD are shown.   (C) Papilloma 
formation in WT and S100A9KO mice after DMBA and TPA treatment as indicated in 
the graph.  Each group composed 7 mice, p=0.003. (D) Number of papillomas in lethally 
irradiated C57BL/6 mice that received BM from S100A9KO or WT (control) mice. 
Carcinogen treatment initiated 3 weeks after the BM transfer. Each group included 4 
mice (p<0.001).  Statistical analysis in (C) and (D) is 2 Way Anova.     
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C D 
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sufficient number of IMC directly from skin for functional tests was not technically   
feasible, Gr-1+CD11b+ cells were isolated from BM of WT and S100A9Tg mice, which 
had been treated for 4 weeks with TPA. No immune suppressive activity of these cells 
in allogeneic mixed lymphocyte reactions (MLR) was detected (Figure 9A). We 
evaluated the possibility that more potent pro-inflammatory signals are needed to 
convert IMC to MDSC in Tg.AC mice, which could mimic the situation in the skin.  We 
used i.p. administration of complete Freund’s adjuvant (CFA), a potent pro-inflammatory 
stimulus. Although CFA induced a substantial expansion of Gr-1+CD11b+ cells (Figure 
9B), these IMC isolated from either WT or from S100A9Tg mice were unable to 
suppress antigen-specific CD8+ T cell responses (Figure 9C). Thus, even when 
activated with potent pro-inflammatory stimulus, IMC in S100A9Tg did not display 
immune suppressive activity.   
Since S100A9Tg mice had reduced presence of CD11c+ DCs in the skin as 
compared with WT mice (Figure 5D), we analyzed in more detail the different 
populations of DCs by using flow cytometry. Only slight differences between WT and 
S100A9Tg mice were seen in the proportion of subsets of skin DCs (Figure 10A), with 
the exception of one population of CD207+CD11b-CD103+ DC, which was significantly 
elevated in S100A9Tg mice compared to WT mice (Figure 10A). S100A9Tg had 
modestly (p<0.01) reduced number of Langerhans cells (LC) in epidermis (Figure 10B). 
To determine if this would translate into decreased migration of DC to draining LN, WT 
and S100A9Tg mice were treated topically with acetone vehicle or TPA for 4 weeks 
after which the skin was painted with fluorescent dye DDAO.  
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Figure 9. Accumulative IMC are not suppressive: (A) Suppressive assay of 
Gr1+CD11b+ IMC cells isolated from BM of mice treated with TPA.  Allogeneic MLR 
were performed using CD3-depleted and irradiate FVBN splenocyte as stimulators and 
BalbC T cells as responders.  Stimulators and Responders were mixed at 1:1 ratio and 
IMC were added as indicated.  Proliferation was measured by Thymidine incorporation.   
(B) The phenotype of cells in spleens of WT and S100A9Tg C57BL/6 mice seven days 
after i.p. injection of 100 µg CFA.  (C) Effect of Gr-1+ cells isolated from BM of CFA 
treated C57BL/6 mice on proliferation of antigen-specific T cells. Gr-1+ cells were mixed 
at different ratios with splenocytes from OT-1 mice in the presence of the specific 
peptide. Top panel - T-cell proliferation measured in triplicates by [3H]-thymidine uptake. 
Bottom panel – the number of IFN-γ producing cells measured in triplicates in ELISPOT 
assay. Two experiments were performed with similar results.   
 
The next day skin-draining LN were collected and DDAO+ DCs were counted. We found 
significantly lower number of DDAO+ CD86+IAbright migratory DCs in LN of S100A9Tg 
mice than in WT mice (Figure 10C).   
We wondered whether reduction in DC numbers and migration in S100A9Tg skin 
could result in impaired priming of CD8+ T cells. S100A9Tg mice were backcrossed for 
9 generations with C57BL/6 mice. DDAO labeled OVA-specific OT-1 T cells were 
 
C 
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transferred to WT or S100A9Tg C57BL/6 mice pretreated for 4 weeks with TPA. OVA 
protein was applied to the same part of the skin as TPA and three days later 
proliferation of OT-1 T cells was evaluated in LN and spleen. Robust proliferation of OT-
1 cells was observed in all mice. No differences were found between WT and 
S100A9Tg mice (Figure 10D). These data indicate that despite reduced presence of 
DCs in the skin, antigen-specific response was unaffected in S100A9Tg mice. Together 
with the data indicating lack of immune suppressive activity of IMC this finding suggests 
that immune suppression is not the primary reason for increased tumor formation in 
S100A9Tg mice. 
 
IMC recruit CD4+ T cells to the skin. We evaluated the presence of 
lymphocytes in the skin of vehicle and TPA-treated mice. No differences between WT 
and S100A9Tg mice were found in the presence of B lymphocytes and NK-cells (Figure 
11A, B) as well as CD8+ T cells (Figure 11C). Treatment with TPA resulted in 
accumulation of CD4+ T cells in the skin that was significantly (p<0.01) higher in 
S100A9Tg mice than in WT mice (Figure 11D). In S100A9KO mice, TPA caused 
modest increase in skin CD4+ T cells compared to the prominent accumulation 
observed in WT C57BL/6 mice (Figure 11E). Skin CD8+ T cells in both WT and 
S100A9KO mice were comparably low and unaffected by TPA treatment (data not 
shown).  
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Figure 10. Characterization of DC in the skin of TPA treated mice:  (A) Phenotype 
of DCs in the skin of WT and S100A9tg mice after TPA treatment measured by flow 
cytometry.  Three experiments combined are shown.  Mean and SD are shown.  ***p< 
0.001.  (B)  Langerhans cells in epidermis of mice. On the top is a typical example of 
staining. Bar graph on the bottom shows cumulative result of the number of LC per 1 
mm2 of epidermis. Each group included 4 mice (mean and SD are shown). ** - p<0.01.  
(C). Migration of skin DCs to draining lymph nodes. Dorsal shaved skins of WT and 
S100A9Tg mice previously treated with acetone or TPA were painted with DDAO and 
24 hours later  DDAO+ CD11c+ cells were evaluated in draining lymph nodes by flow 
cytometry. Each experiment was performed 3 times.  (D) T cells from OT1 mice were 
labeled with DDAO fluorescent dye and injected i.v.  into TPA treated WT and 
S100A9Tg C57BL/6 mice. OVA was applied to the skin 24 hr later and LN and 
CD8+CD45.1+ T cells spleens were evaluated by flow cytometry 3 days after the 
application. A typical example of the CD8+CD45.1+ T cell proliferation is shown on the 
left, and cumulative results (mean + SD) of three mice in each group is shown on the 
right.  
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Figure 11.  IMC recruit CD4+ T cells to the skin: The proportion of B cells (A) and NK 
cells (B) cells among CD45+ hematopoietic cells in WT and S100A9Tg mice treated 
with TPA and evaluated by flow cytometry. Each group included three mice. Mean and 
SD are shown. C-E. The number of CD8+ (C) and CD4+ (D) T cells in the skin of WT 
and S100A9Tg FVB/N mice and CD4+ T cells (E) in the skin of WT and S100A9KO 
C57BL/6 mice. The number of cells was evaluated by IHC and counted per mm2 of 
tissue (*- p<0.05, ** - p<0.01). Mean and SD are shown. Each experiment included 5 
mice.  
 
The characteristics of CD4+ T cells in skin of TPA treated mice were studied 
using flow cytometry. Consistent with the data obtained by IHC, the proportion of CD4+ 
T cells among hematopoietic CD45+ cells in skin was significantly (p<0.001) higher in 
S100A9Tg mice than in WT mice (Figure 12A). The prevalence of different subsets 
within the population of CD4+ T cells in skin was measured using intracellular cytokine 
staining. No substantial differences were found between WT and S100A9Tg mice in the 
proportion of most CD4+ T-cell populations.  
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However, S100A9Tg skin showed higher proportion of IL-22+ and IL-10+ cells, 
and FoxP3+CD4+ Treg and a significantly lower proportion of IL-13+CD4+ cells than WT 
skin (Figure 12B). No differences were seen between WT and S100A9Tg skin treated 
with acetone vehicle alone (data not shown). To investigate the ability of IMC to directly 
polarize CD4+ T cells in vitro, naïve CD4+CD62L+ T cells were cocultured with IMC 
isolated from BM of TPA treated WT or S100A9Tg mice. No evidence of CD4+ T cell 
polarization was found (Figure 12C). Thus, accumulation of IMC in skin of S100A9Tg 
mice was associated with substantial increase in the presence CD4+ T cells. Although 
IMC did not cause specific polarization of CD4+ T cells, they recruited substantial 
proportion of pro-inflammatory T-cell populations.  Since accumulation of IMC in the 
skin correlated with increased infiltration of CD4+ T cells, we investigated whether 
enhanced tumor formation in S100A9Tg mice was mediated by CD4+ T cells. 
S100A9Tg; Tg.AC bitransgenic mice were treated with control IgG or CD4-specific 
antibody before and during the first three weeks of TPA application. CD4 antibody 
significantly (p<0.01) reduced the formation of papillomas in these mice (Figure 12D) 
indicating that tumor promoting effect of IMC is mediated via recruitment of CD4+ T 
cells.  
The mechanism of IMC inducible recruitment of CD4+ T cells.  We evaluated 
the ability of IMC to attract CD4+ cells in vitro. Supernatants from normal BM derived 
IMC had no effect on CD4+ T cell migration. However, IMC activated with LPS or TPA 
secreted potent chemotactic activity for CD4+ T cells (Figure 13A). Importantly, 
chemotaxis of CD4+ T cells was observed only if T cells were stimulated prior to the 
assay (Figure 13A). When IMC supernatants were placed in both chambers during the 
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assay, CD4+ T cell migration was significantly reduced indicating that the effect was 
indeed the result of chemotaxis (Figure 13B). 
 
                                               
                                                                     
Figure 12. Characterization of T cell from skin of S100A9tg and WT mice: (A) The 
proportion of CD4+ cells among CD45+ hematopoietic cells in the skin of WT and 
S100A9Tg mice treated with TPA and evaluated by flow cytometry. Six mice per group 
(*** - p<0.001). (B) Intracellular staining of different cytokines in cells isolated from the 
skin of WT and S100A9Tg mice treated with TPA. CD4+ cells were gated. Each group 
included 3-6 mice(*p<0.05). (C) Polarization of CD4+ T cells in vitro.  Naïve 
CD4+CD62L T cell were culture with IMC isolated from BM cells at 1:1 ratio in the 
presence of CD3+CD28+ beads for 4 days. Then cells were treated with 
PMA/ionomycin in the presence of Golgi-stop for another 4 hours.  Intracellular staining 
was evaluated within CD4+ population.  Total of 5 Mean and SD of 5 experiment are 
shown.  (D) Papilloma development in CD4 depleted S100A9Tg; Tg.AC bitransgenic 
mice. CD4 antibody or IgG (control) treatment was performed as indicated on the graph. 
Mean and SD of papillomas per mouse are shown. Each group included 5 mice 
(p=0.021).    
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Figure 13. Activated IMC induce CD4+ T cells migration:  (A) Chemotaxis of CD4+ T 
cells isolated from control mice to supernatant from IMC. IMC were either stimulated or 
not with LPS. T cells were stimulated or not with CD3/CD28 antibody. CD4+ T cells were 
placed in the top chamber and supernatants (30% v/v) in the bottom chamber. For 
control, LPS was added to the medium in the bottom chamber. Cumulative results of 6 
independent experiments are shown (*** - p<0.001)  (B) Splenocytes were activated 
with anti-CD3 and placed in the top chamber of Transwell plates.  Then supernatant of 
activated IMC were placed in the bottom or both top and bottom of the Transwell. The 
proportion of CD4+ cells were evaluated by flowcytometry.  Mean and SD are shown 
from 3 experiments. P<0.05  
 
Using RNA isolated from skin, we examined expression of chemokines known to 
be involved in the migration of CD4+ T cells. Expression of ccl3 and ccl4 RNAs were 
significantly (p<0.05) upregulated in the skin of TPA treated S100A9Tg mice compared 
to WT mice, whereas the expression of ccl22 was modestly increased (Figure 14A). 
However, no differences in the amount of CCL3 and CCL22 proteins were found in skin 
lysates of TPA treated S100A9Tg and WT mice (Figure 14B). In contrast, the amount of 
CCL4 in the skin of TPA-treated S100A9Tg mice was significantly higher than in WT 
mice. No differences in the amount of CCL4 were observed in spleens, BM, lung, or 
liver (Figure 14C). Since skin was the primary site of IMC accumulation in TPA treated 
S100A9Tg mice, this data is consistent with IMC as the primary source of CCL4. To 
A B 
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verify that IMC are indeed able to produce CCL4, this chemokine was measured in 
supernatants from BM IMC isolated from TPA treated WT and S100A9Tg mice. Large 
amount of CCL4 was found in supernatants from stimulated IMC (Figure 14D). To verify 
the role of CCL4 in CD4+ T-cell recruitment by Gr-1+ myeloid cells, we added 
neutralizing CCL4 antibody to IMC supernatants in chemotaxis assay. CCL4-specific 
antibody abrogated CD4+ T-cell migration caused by IMC in a dose-dependent manner 
(Figure 14E).  
To test the role of CCL4 in vivo, WT and S100A9Tg mice were treated for 4 
weeks with control or CCL4 antibody concurrent with TPA. Treatment with CCL4 
antibody did not affect the presence of Gr-1+ myeloid cells (Figure 15A) or CD8+ T cells 
(Figure 15B) in the skin. In contrast, neutralization of CCL4 significantly (p<0.01) 
reduced the presence of CD4+ T cells in WT and S100A9Tg skin (Figure 15C). Weekly 
treatment of Tg.AC mice with CCL4 antibody during the first 3 weeks of TPA promotion 
dramatically reduced the formation of tumors (p<0.01) (Figure 15D).  Similar 
experiments were performed in S100A9Tg; Tg.AC bitransgenic mice, that developed 
much higher number of papillomas than Tg.AC mice, but the CCL4 antibody still 
drastically (p<0.01) reduced the number of tumors (Figure 15E).   
 
Discussion       
In this study, we report that IMC directly contribute to skin tumor development via 
recruitment of CD4+ T cells. Although the link between inflammation and cancer is well 
established,5,32  the contribution of specific cell populations to the initial phase of tumor   
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Figure 14. CCL4 is responsible for the recruitment of CD4+ T cells to the skin:  (A) 
qRT-PCR analysis of the expression of ccl3, ccl4, ccl5, and ccl22 in skin of WT or 
S100A9Tg mice treated with TPA or acetone. Differences in expression of ccl3 and ccl4 
were significant *P<0.01. (B) Amount of CCL22 (left) and CCL3 (right) protein measured 
by ELISA in lysates of various organs from TPA treated WT and S100A9Tg mice. Mean 
and SD from 4 experiments with 3 mice per group are shown. Each measurement was 
performed in duplicate and normalized for total protein. Cumulative results from three 
experiments are shown. (C) Amount of CCL4 protein measured by ELISA in lysates of 
various organs from TPA treated WT and S100A9Tg mice. Mean and SD from 4 
experiments with 3 mice per group are shown. Each measurement was done in 
duplicate normalized for total protein (** - p<0.01). (E) Neutralizing CCL4 antibody 
inhibited migration of activated CD4+ T cells towards supernatant obtained from LPS 
stimulated IMC. Concentrations of CCL4 antibody or IgG are shown in the graph. Two 
experiments were performed in duplicate (** - p<0.01). 
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development remains unclear. The role of MDSC in tumor immune escape is now well 
established. In recent years, evidence pointed to expansion of MDSC in chronic 
infection and inflammation. This raised the question as to whether these cells contribute 
to tumorigenesis directly or via differentiation to MΦ. MΦs participate in early stages of 
cancer and inflammation.408  Because inflammation is so complex, the specific role of 
individual cell populations in tumor promotion is difficult to ascertain. S100A9Tg mice 
provide a novel experimental model in which tissue accumulation of cells with IMC 
phenotype is not caused by infection, trauma, or cancer.  This accumulation was 
especially evident in TPA treated mice. The vast majority of myeloid cells accumulated 
in skin of S100A9Tg were granulocytic IMC. It is known that activated keratinocytes can 
attract granulocytes via release of CXCL8 chemokine.409  This may provide a signal for 
initial influx of IMC to TPA treated skin. Though these IMC could be classified as PMN- 
MDSC, they lack immune suppressive activity even after additional stimulation with 
various pro-inflammatory stimuli in vitro or in vivo. Consistent with our previous study,167 
accumulation of IMC did not result in elevation of MΦ or DC. Although the number of 
DCs migrating from skin to LN was decreased, the priming of CD8+ T cells to topical 
antigen was not affected. Apparently, the modest decrease in DCs in skin was not 
sufficient to inhibit CD8+ T-cell priming. Alternatively, the significantly higher proportion 
of CD11b-CD207+CD103+ DCs in S100A9Tg mice may have compensated because 
these cells play a major role in cross-presentation of antigens in the skin.410 Collectively, 
these data indicate that enhanced papilloma formation in S100A9Tg mice is not due to 
immune suppression as typically observed with MDSC in cancer. Our results with BM 
transfers and Gr-1-specific antibody depletions in S100A9Tg mice, as well as 
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decreased skin carcinogenesis in S100A9KO mice, demonstrate that IMC were the 
primary facilitator of tumor development. 
It is known that granulocytic cells may potentially contribute to neoplastic 
transformation via multiple mechanisms including increased rate of mutation and 
proliferation of cells via release of reactive oxygen species411-413 activation of 
cyclooxygenase-2 in epithelial cells414 and inhibition of nucleotide excision repair in 
epithelial cells lines by  myeloperoxidase.415-417  In this study we did not evaluate the 
malignant conversion of tumor lesions but focused on the earlier events promoting 
papilloma formation. We found close correlation between accumulation of IMC and 
CD4+ T cells in TPA treated skin. It suggested that IMC could recruit CD4+ T cells. 
Indeed, direct in vitro experiments confirmed this hypothesis. Importantly, only activated 
IMC were able to recruit CD4+ T cells. IMC recruited different population of CD4+ T 
cells. However, S100A9Tg skin had increased (albeit not statistically significant) 
presence of IL-22+ pro-inflammatory CD4+ T cells. It was associated with dramatic 
decrease in IL-13 producing CD4+ T cells. IL-13 was previously shown to be a negative 
regulator of Th17 cells.418  
CD4+ T cells and specifically IL-17 and IL-22 producing subsets have been 
implicated in tumor development. Deficiency of CD4+ T cells inhibited tumor 
development in 2-stage squamous carcinogenesis model,419 and enhanced cancer 
progression in methylcholantrene (MCA)-initiated sarcoma development.420 In the 
K14HPV16 skin cancer model, with E6/E7 oncogenes expressed in epidermis from 
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Figure 15. IMC effect on papilloma formation is mediated via CCL4: (A) S100A9Tg 
mice were treated for 4 weeks with TPA and either control IgG or neutralizing CCL4 
antibody.  Typical example of staining and the number of Gr-1+ cells in the skin (right 
panel). (B)The number of CD8+ cells in skin.. (C)  Typical example of staining and the 
number of CD4+ cells in the skin.  Each group included three mice (**p<0.01). Scale bar 
= 100µm. (D) The number of papillomas formed in Tg.AC and (E)  S100A9Tg;Tg.AC 
mice treated with TPA and control IgG or  CCL4 antibody  as indicated. Mean and SD 
are shown. Each group included 4 mice. P=0.001 (D) and P<0.001 (E).  
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keratin 14 promoter, CD4 deficiency drastically attenuated neoplastic progression.229  
Pro-tumorigenic effect of CD4+ T cells were primarily associated with accumulation of 
immune suppressive Tregs and pro-inflammatory Th17 cells via release of IL-17, IL-21, 
and IL-22.421,422  It was suggested that IL-17 and IL-22 contributes to tumor 
development by inducing angiogenesis or directly affecting keratinocyte proliferation 
and survival.423,424 IL-17 was also shown to promote accumulation of cells with MDSC 
phenotype286 suggesting a feedback mechanism contributing to tumor development. IL-
17 KO mice in a 2-stage carcinogenesis showed delayed papilloma formation compared 
to WT mice.291 
The critical role of CD4+ T cells in papilloma formation has been validated in our 
study. Our results further reveal a mechanism in which IMC accumulated in skin recruits 
large numbers of CD4+ T cells, including pro-inflammatory populations. We identified 
CCL4 chemokine as the main factor responsible for IMC mediated recruitment of CD4+ 
T cells.  
CCL4 or MIP-1β is a 69 amino acid member of the β (CC) family of chemokines. 
It is produced by various cells, including myeloid cells, and binds to CCR1, CCR5 and 
US28 receptors. It was reported that melanoma associated MDSC produce high levels 
of CCL4 among other chemokines and in CCR5-deficient mice, growth of transplantable 
tumors was delayed.425 Activated CD4+ T cells upregulate CCR5 receptor, allowing 
these cells to be recruited to the site of CCL4 production426,  which is consistent with our 
finding that IMC attracted only activated CD4+ T cells. Although it was reported that 
different CD4+ T cell subsets may express unique repertoires of chemokine receptors,  
current evidence suggests that CCR5 can be expressed on recently activated cells of 
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any subset,427 consistent with lack of preferential accumulation of specific populations of 
CD4+ T cells in the skin of S100A9Tg mice.  
Our data suggest sequence of events which may promote tumor formation in skin 
and possibly other tissues. Granulocytic IMC accumulate at the site of cutaneous 
irritation or inflammation triggered by TPA treatment.  Activated IMC release CCL4 that 
recruits CD4+ T cells including pro-inflammatory populations. These T cells release IL-
17 or IL-22 to stimulate proliferation of keratinocytes and promote tumor formation 
(Figure 16). The direct effect of IMC on keratinocytes or epithelial cells in other tissues 
merits further investigation, as well as the possibility that targeting IMC may benefit 
individuals with high risk of cancer development. 
 
Methods  
Mice. All animal experiments were approved by University of South Florida 
IACUC. Mice were housed in pathogen-free facilities. Tg.AC mice were described 
previously426  and obtained from Taconic (Rensselaer, NY). S100A9Tg mice on FVB/N 
background167  and S100A9KO mice on C57BL/6 background194 were described 
previously. Balb/c, C57BL/6, and FVB/N mice were obtained from National Cancer 
Institute (Frederick, MD). OT-1 mice were obtained from Jackson Labs. In 
S100A9Tg;Tg.AC bitransgenic mice the presence of S100A9-IRES-GFP transgene was 
verified by the expression of GFP in leukocytes from peripheral blood and the v-h-ras 
transgene was detected by genomic PCR for the SV40 sequences. In some 
experiments, S100A9Tg mice on C57BL/6 background were used after backcrossing 
S100A9Tg FVB/N mice with C57BL/6 mice for 9 generations.  
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Figure 16. Illustration of potential mechanism of IMC to induce tumor 
development: Upon tumor promoter induction, inflammation is developed and recruits 
IMCs from the BM to the targeted tissue.  These bone marrow-derived cells can secrete 
more inflammatory molecules, such as S100A9 which sustains the inflammatory 
environment.  More importantly, these IMCs are able to secrete the inflammatory 
chemokine CCL4, which is able to mobilize CD4+ T helpers cells into the same targeted 
tissue.   
 
 
Skin Carcinogenesis.  Female, aged matched (7-10 weeks old) littermate mice were 
used in experiments with Tg.AC and S100A9Tg;Tg.AC mice. Dorsal skin was shaved 
and 3 nmoles of TPA (Sigma) in 200 µl acetone vehicle was applied twice a week for 4 
or 6 weeks.  In the carcinogenesis model in C57BL/6 or S100A9KO mice 100 nmoles of 
single dose of 7,12-Dimethylbenz(a)anthracene (DMBA) was applied followed by 10  
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by 10 nmoles of TPA every 24 hours for 12 weeks, as previously described.428 
Papillomas were assessed weekly and counted when they reach 1mm for at least 2 
weeks. In bone marrow transfer experiments, lethally irradiated (950 rads) mice were 
injected i.v. with 106 BM cells from various donors’ mice. Treatments with TPA or DMBA 
and TPA started 3 weeks after the transfer and were performed as described above.   
 
Tissue preparation and histology.  Slides with frozen tissues were fixed for 10 
minutes with acetone and blocked for 60 min with 10% goat serum, 1% BSA and 2.5% 
mouse serum in PBS at room temperature. The following primary antibodies from BD 
biosciences were used at 1:100 dilutions: Gr1 (RB6-8C5), CD4 (H129.19), and CD8 
(53-6.7). The following antibodies from ebioscience were used at 1:50 dilution: CD11c 
(N418) and F4/80 (BM8). Biotinylated anti-rat IgG (Vector Labs) or anti-hamster IgG 
(Vector Labs) were used as secondary antibodies. Alkaline phosphatase kit and Vector 
Red substrate (Vector Labs) were used for visualization of the results. The tissues were 
counterstained with hematoxylin and mounted for cell counting. Images were taken by 
the digital slide scanner Scanscope (Aperio) and analyzed by Aperio software. Cell 
number was calculated per 1 mm2. 
 
Cytokine expression measured by qPCR and ELISA.  For the analysis of 
gene expression, the total RNA was extracted with a Trizol reagent (Invitrogen), and 
cDNA was synthesized using the High Capacity cDNA Reverse Transcriptase kit 
(Applied Biosystems). To detect mouse chemokines, PCR was performed with 2 μl of 
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cDNA, 12.5 μl of SYBR Master Mixture (Applied Biosystems). Primers used for the 
different chemokines were the followings: ccl2: forward 5’-CCC AAT GAG TAG GCT 
GGA GA-3’ and reverse 5’-AAA ATG GAT CCA CAC CTT GC-3’, ccl3 forward 5’- CCA 
AGT CTT CTC AGC GCC ATA-3’and reverse 5'-GAT GAA TTG GCG TGG AAT CTT 
C-3', ccl4 forward 5'-TGC TCG TGG CTG CCT TCT-3' and reverse 5'-CTG CCG GGA 
GGT GTA AGA GA-3', ccl5 forward 5’-TGC CCA CGT CAA GGA GTA TT-3’ and 
reverse 5’-CAG GAC CGG AGT GGG AGT A-3’, ccl9 forward 5′-GAT GAA GCC CTT 
TCA TAC TGC -3′ and reverse 5′-GTG GTT GTG AGT TTT GCT CCA ATC -3′ and 
ccl22 forward 5′-GTG GCT CTC GTC CTT CTT GC-3′ and reverse 5′-GGA CAG TTT 
ATG GAG TAG CTT-3′.  Amplification of endogenous β-actin was used as an internal 
control. For evaluation of the proteins, BM cells were flushed and tissues were 
homogenized in RIPA buffer for protein extraction.  Chemokines’ proteins were 
measured by ELISA using the kits PeproTech (Rocky Hill, NJ):  CCL3 (900-K125), 
CCL4 (900-K278), or CCL22 (900-K197). 
 
Western Blot.  Samples (30ug protein per lane) were subjected to 
electrophoresis in 12 % SDS-polyacrylamide gels, and then blotted onto PVDF 
membranes. Membranes were blocked for 1 hour at room temperature with 5% dry skim 
milk in TBS (20nM Tris-HCl. pH 7.6, 137mM NaCl plus 0.1% (v/v) Tween 20) and then 
probed with S100A9 or β-actin specific antibodies (Santa Cruz) followed by secondary 
antibody conjugated with horse radish peroxidase. Results were visualized by 
chemoluminescence detection using commercial kit (GE Bioscience).  
 
   95 
Experiments with depletion of cells and neutralization of chemokine in 
vivo. Mice were injected intraperitoneal (i.p.) with 250 µg of CD4 (clone: GK1.5, 
BioXCell), Gr-1 (clone: RB6-8C5, BioXCell), or 100 µg of CCL4 (R&D System) specific 
monoclonal antibodies. Injections were performed once a week for 4 weeks starting one 
week before beginning of TPA treatment. Control groups in CD4 and Gr-1 depletion 
experiments received Rat IgG2b Isotype (clone: LTF2, BioXCell), in CCL4 neutralization 
experiments received goat IgG (RD System). 
 
CD4+ T cell polarization experiments.  Naïve CD62L+CD4+ T cells were 
isolated from spleen of FVB/N mice using magnetic beads (Miltenyi) and coculture with 
Gr-1+ cells isolated from BM of WT or S100A9Tg mice treated for 4 weeks with TPA. 
Cells were activated for 4 days at 37ºC with CD3/CD28 beads. On day 4 cells were 
stimulated with 50 ng/ml of TPA and 700 ng/ml of ionomycin for 4 h in the presence of 
protein transport inhibitor GolgiStop (BD PharMingen) to prevent cytokine secretion 
during the last 3 hr. The cells were harvested followed by intracellular staining with CD4, 
IL-17, IL-4, FoxP3, or IFNγ antibodies (all from BD bioscience) and analysis by flow 
cytometry. 
 
Skin cell isolation and analysis.  Pieces of shaved skin were incubated in PBS 
containing 0.2% trypsin for 30 min at 37ºC, cut into small pieces and incubated with 0.8 
mg/ml of collagenase in RPMI for 40 minutes at 37ºC. Single cell suspension was 
prepared by pressing tissues through 100 µm cell strainer. For the analysis of cell 
phenotype, cells were used directly for flow cytometry. Nonspecific staining was blocked 
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by Fc-block (BD) and staining was performed in 1% FBS. The cells were analyzed by 
flow cytometry using a LSR II cytometer (BD Biosciences) and FlowJo software (8.6). 
Dead cells were excluded by DAPI-staining, and CD45+ cells were analyzed. For the 
analysis of intracellular cytokines, mononuclear cells were isolated by density 
centrifugation on Ficoll-Paque, washed and plated at 2x106/ml concentration in round-
bottom 96 well-plates. Cells were then stimulated with 30 ng/ml TPA and 750 ng/ml 
ionomycin for 4 hr, the last 3 hr in the presence of GolgiStop. Cells were stained by 
Live-Dead Violet followed by CD45 and CD4 antibodies. After fixation and permeation, 
cells were stained for intracellular cytokines or FoxP3 and analyzed by flow cytometry. 
  
Chemotaxis.  Gr-1+ cells were isolated from BM using biotinylated anti-Gr1 
antibody and streptavidin microbeads (Miltenyi Biotec). The purity of Gr-1+CD11b+ cells 
was greater than 95%. Cells were cultured overnight in serum-free medium (Cellgenix) 
at 106/ml, in the presence or absence of 0.5 µg/mL of LPS. Supernatants were collected 
after 24 hr and added at 30% v/v to the bottom chamber of Transwell plates (5 µm 
pores) in a total volume of 500 µL of serum-free medium. To activate T cells, 
splenocytes were cultured with 0.5 µg/ml of anti-CD3 antibody for 3 days in serum-free 
medium. One million of stimulated or nonstimulated splenocytes were resuspended in 
100 ul of serum-free medium and added to the top chamber of the Transwell. After 4 hr 
incubation at 37ºC, CD4+ T cells that passed through the membrane to the lower 
chamber were measured by flow cytometry.   
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Langerhans cell staining.  Dorsal skin sheets were prepared as previously.429 
The epidermal sheets were fixed in acetone for 1 minute, blocked with 1% BSA and 
stained overnight at 4ºC with IA/IE-PE antibody (clone 2G9, BD bioscience) at 1:100 
dilution. Next day, the sheets were washed stained with secondary antibody and 
mounted on slides. The staining was analyzed in SP5 Leica Confocal Microscope.  
 
DC migration and T cell proliferation.  Shaved dorsal skin was painted with 0.4 
ml of a 1:1 mixture of acetone:DBP containing 250 µM DDAO (Invitrogen). 24 hr later, 
draining LNs were collected, treated with 1 mg/ml collagenase in PBS/BSA for 30 min, 
and single cell suspensions were stained and analyzed by flow cytometry.  For the 
analysis of in vitro cell proliferation, 105 splenocytes from Balb/c mice (responders) were 
mixed with 105 T-cell depleted and irradiated (20Gy) splenocytes from FVB/N mice 
(stimulators) in U-bottom 96 well-plates. Gr-1+ cells from TPA treated S100A9Tg or WT 
mice were added into wells at different ratios. On day 4 cells were pulsed with 3H-
thymidine (1 µCi/well; GE Healthcare) for 18 hours. 3H-thymidine uptake was counted 
using a liquid scintillation counter and expressed as counts per minute (cpm).For the 
assessment of in vivo T-cell proliferation in response to antigens, splenocytes and LN 
cells collected from OT-1 CD45.1+ mice were labeled with 5 µM DDAO. Eight million of 
DDAO labeled OT-1 cells were injected into the tail vein of C57BL/6 (CD45.2+) WT and 
S100A9Tg mice that were pretreated for 4 weeks with TPA. The day after transfer, 10 
mg of OVA protein in 500 µL of Ultrasicc gel was applied onto the shaved dorsal skin of  
the mice. Three days later skin-draining LNs and spleen were collected. Cells were 
stained and analyzed by flow cytometry.   
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Statistical Analysis.   Statistical analysis was performed using unpaired 2-tailed 
Student t-test with significance determined at p<0.05. For the analysis of papilloma 
formation statistical significance of repeated measurements was assessed using two-
way ANOVA test.  
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CHAPTER 3. MYELOID-DERIVED SUPPRESSOR CELLS IN THE 
DEVELOPMENT OF LUNG CANCER  
 
Rationale 
Lung cancer is the leading cause of death among men and women in the United 
States.24  It is predicted that lung cancer will caused more deaths than the three most 
common cancers combined (colon, breast, and prostate).24  Tobacco smoke is the 
principal cause of small cell and non-small cell lung cancer and contributes to more than 
80 percent of lung cancer deaths among men and women.24  Tobacco smoke also has 
been related to the development of cancer in mouth, lips, pharynx, larynx, esophagus, 
pancreas, uterus, colon, bladder and acute myeloid leukemia, besides lung cancer.47  
Cigarettes are a complex mix of over 4000 chemical agents that includes lung 
carcinogens.37,38  The metabolic activation of this compounds cause genetic alterations 
to the DNA resulting in the development of cancer.37  Tobacco smoke also can cause 
pulmonary inflammation, which can contribute to the progressive development of lung 
cancers.  Pro-inflammatory changes have been identified in the lungs of active smokers 
but interestingly it also has been notice these transformations in patients after they stop 
smoking.430  This can generate smoking-independent oxidant stress thus explaining the 
persistence and progression of the disease after smoking has been discontinued.431    
The most appropriate model to recapitulate the complexity of the effect of CS on 
mice is a smoking chamber where mice are exposed to tobacco smoke for prolonged 
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periods of time. This approach, however, requires a very long exposure of mice to 
smoke and results in the development of lung cancer only in a proportion of mice.432  To 
achieve the development of cancer, in this model we used urethane as carcinogen to 
induce lung cancer.78,433 In our smoking model, CS caused strong accumulation of IMC 
lacking immune suppressive activity. To clarify the role of MDSC in the development of 
lung cancer we used S100A9 knockout mice.  S100A9 was implicated in abnormal 
differentiation of myeloid cells in cancer accumulation of MDSC.434   Using this 
experimental model we tested the hypothesis that MDSCs are directly involved in the 
development of lung cancer.  We found that bonafide MDSCs are important for tumor 
progression and their presence negatively affects survival of the mice but further 
suggests that tobacco smoking can contribute to the development of lung cancer by 
inducing the accumulation of non-suppressive IMC.  The presence of IMCs, although 
are not suppressive, contributes in the chronic inflammation that has a tumor promoting 
effect. 
 
Results 
Exposure of mice to cigarette smoke induces expansion of myeloid cells in 
mice.  To clarify the role of MDSC in lung cancer directly associated with inflammation, 
we used CS model in FVB/N mice. First, we asked whether CS alone affected the 
presence of different populations of myeloid cells. CS did not change the total number 
of leukocytes (data not shown). However, one-month exposure to CS caused a 
significant (p=0.01) increase of the presence of Gr-1+CD11b+ cells in PB. Granulocytic 
and monocytic subsets were equally increased and their ratio remained unchanged 
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(Figure 17A). Three-month exposure of mice to CS did not further increase the 
presence of Gr-1+CD11b+ cells in PB. It remained two-fold (p=0.003) higher than in 
control. However, the dramatic re-distribution of myeloid cells towards granulocytic cells 
was evident (Figure 17B). Despite some trend to an increase in mice exposed to CS, 
the presence of MΦ and DCs was not significantly different from non-treated mice 
(Figure 17B).  
  
Figure 17. The proportion of myeloid cells in peripheral blood of mice exposed to 
CS: FVB/N were exposed to CS for (A) one and (B) three months. The proportions of 
indicated population of myeloid cells were evaluated. Each group included 3 mice. 
 
Myeloid populations in bone marrow (BM), spleens, and lungs were evaluated 
after 4 months of CS. Exposure to CS caused significant (p<0.05) increase of the 
presence of Gr-1+CD11b+ cells in all tested organs. In spleens this increase was 
associated with preferential accumulation of granulocytic cells (Figure 18). The 
population of MΦ had not changed in any tested organ, whereas the proportion of DCs 
was significantly decreased in lung (Figure 18). 
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Figure 18. The proportion of myeloid cells in different organs of mice exposed to 
CS:  Mice were exposed to CS for 4 months and the proportions of indicated 
populations of myeloid cells were evaluated in different organs. Each group included 3-6 
mice. The proportions of cells isolated from lungs were calculated among CD45+ 
hematopoietic cells 
 
 
Thus, CS caused substantial increase in the presence of Gr-1+CD11b+ cells, 
which could be represented by MDSC. We evaluated the immune suppressive activity 
of these cells. Gr-1+CD11b+ cells were isolated from spleens, lung, or BM and tested in 
different assays. These cells did not affect CD3/CD28 inducible T cell proliferation 
(Figure 19A) or T cell proliferation in allogeneic mixed leukocyte reaction (Figure 19B). 
These results indicate that CS by itself caused substantial accumulation of IMC with 
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granulocytic phenotype. However, these cells lacked immune suppressive activity, and 
thus were not bona fide MDSC.  
 
 
Figure 19. Gr-1+CD11b+ myeloid cells from mice exposed to CS do not suppress T 
cell proliferation: (A) Splenocytes from naïve FVB/N mice were stimulated with CD3 
and CD28 specific antibodies in the presence of Gr-1+CD11b+ IMC purified from control 
mice and mice exposed to CS at indicated IMC: splenocyte ratios. T cell proliferation 
was measured in triplicated by [3H] thymidine incorporation. Each group included 3 
mice.  (B) Purified IMCs from spleen or lung of smoking or control FVB/N mice were 
added at indicated ratios to a mixed lymphocyte reaction, which was set up using 
splenocytes from BALB/C mice as responders and irradiated splenocytes from FVB/N 
mice as stimulators mixed at 1:1 ratio. T cell proliferation was measured in triplicates by 
[3H] thymidine incorporation. Mean and SEM from 3 experiments are shown. 
 
 
MDSC are critically important for tumor progression.  To assess possible 
roles of MDSC in the development and progression of lung tumors, wild-type and 
S100A9KO FVB/N mice were treated with a single injection of urethane and 4-month 
exposure to CS. This treatment resulted in the appearance of a small number of tumor 
lesions (Figure 20A). No significant differences in the number of lesions were found 
between WT and S100A9KO mice at that time (Figure 20B). However, in contrast to Gr-
1+CD11b+ cells isolated from spleens of mice exposed to CS alone, the cells with the 
A B 
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same phenotype isolated from mice treated with urethane and CS and bearing lung 
tumors, had potent immune suppressive activity (Figure 20C). After 4 months of 
treatment wild-type mice had significant increase in the presence of MDSC, but not MΦ, 
in spleens and lungs (Figure 20D). The number of MDSC in S100A9KO mice was 
significantly lower, similar to the level seen in untreated mice (Figure 20D). The number 
of MΦ in S100A9KO mice was lower in spleens but not in lungs (Figure 20D). MDSC 
isolated from spleens of S100A9KO mice had significantly lower T cell suppressive 
activity than MDSC from wild-type mice (Figure 20C).  
In a separate set of experiments, we evaluated whether lack of S100A9 had an 
effect on the survival of mice treated with urethane and CS. The fate of the mice was 
drastically different. All wild-type mice succumbed to the diseases within 5 months after 
start of the treatment. In contrast, all S100A9KO mice were alive at that point (p=0.005) 
(Figure 20E). Thus, CS, by itself, caused expansion of IMC lacking immune suppressive 
activity. Bona fide MDSC accumulated only after the appearance of tumor lesions in 
lung. These cells, however, played a major role in tumor progression and survival of the 
mice.  
 
Discussion  
In this study we investigated the possible contribution of MDSC to the 
development of lung cancer. Although ample evidence linked inflammation and cancer, 
the nature of the cells directly involved in the process of tumor development remained 
unclear. This is especially true for lung cancer. CS is the major cause of lung cancer, 
and inflammation is intimately associated with smoking. Since MDSC are shown to be  
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Figure 20. The effect of S100A9 deletion on tumor progression in mice exposed to 
urethane and CS: WT and S100A9KO FVB/N mice were treated with a single injection 
of urethane (1.5g/kg) and 4 months of CS. A. Typical example of lung tissue staining 
with H&E. Scale Bars = 1 µm. B. The number of tumor lesions per lung. C. Immune 
suppressive activity of Gr-1+CD11b+ cells isolated from spleens of mice assessed in 
allogeneic mixed leukocyte reaction. Each group included 3 mice. Mean and SEM are 
shown. The differences between groups: ** - p<0.01; *** - p<0.001. The differences 
from “No MDSC” control were significant (p<0.05) in all groups except at 1:4 ratio. D. 
The number of indicated myeloid populations in spleens and lungs of mice. * - p<0.05 
between the groups. E. Survival of mice of WT (n=6) and S100A9KO (n=7) mice treated 
with urethane and CS.             
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an inherent part of chronic inflammation, it was tempting to speculate that MDSC may 
be directly involved in the early stages of lung tumor development associated with 
chronic inflammation. We expected that in a lung cancer associated with CS-
inflammation accumulation of MDSCs could happen earlier during treatment. Indeed, 
even a one-month exposure of mice to CS led to an increased presence of Gr-
1+CD11b+ cells in PB, and 4 months of CS caused significant increase of these cells in 
lung and spleen. These cells were largely represented by granulocytic subset.  
However, contrary to our expectations, these cells lacked immune suppressive activity 
indicating that they were not bona fide MDSC. Immune suppressive MDSC 
accumulated in these mice only after the development of tumor lesions. These data 
suggest that in this smoking model, MDSC accumulation was also the result of tumor 
formation. Our results are largely consistent with previous reports demonstrating 
association of lung tumor formation caused by urethane injection with accumulation of 
Gr-1+CD11b+ cells. However, whether those cells had immune suppressive activity was 
not clear.435 
These data indicate that CS, despite causing expansion of IMC, was not 
sufficient to convert them to MDSC. These results are consistent with two-signal 
concept of MDSC accumulation in cancer165 suggesting that the expansion of IMC cells 
and their conversion to MDSC phenotype is governed by different factors and signaling 
pathways. Some factors involved in expansion of IMC are well characterized (GM-CSF, 
M-CSF). However, the mechanism responsible for MDSC conversion is largely unclear 
and needs to be determined. Although bona fide MDSC are not present in mice until 
appearance of tumor lesions, these cells are critically important for the survival of the 
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mice. We addressed the role of MDSC in the natural history of lung tumor progression 
by using S100A9KO mice. S100A9 and its dimerization partner S100A8 proteins play 
an important role in myeloid cell differentiation. Their expression is found predominantly 
in cells of the myeloid lineage. Differentiation of myelocytes and granulocytes is 
associated with increase of S100A8/A9 expression, whereas differentiation of MΦ and 
DCs is associated with loss of these proteins.186,436  Lymphocytes and most of the 
tissues do not express these proteins. We, and others, have shown that accumulation of 
MDSC and inhibition of DC differentiation in cancer were closely correlated with up-
regulation of S100A8/A9.  S100A8/A9 proteins were implicated in lung cancer 
progression. In an early study, S100A8 and S100A9 were shown to be important in 
attracting CD11b+ cells to pre-metastatic lung. Neutralizing anti-S100A8 and anti-
S100A9 antibodies blocked the morphological changes and migration of tumor cells and 
CD11b+ myeloid cells.389  Patients with lung cancer overexpressing S100A9 had a 
significantly lower 5-year overall survival rate than patients with weak or no expression 
of S100A9. Overexpression of S100A9 was an independent factor predictive of poor 
disease outcome.437  Consistent with these data, another study also found association 
of the expression of S100A8/A9 in stromal cells with negative outcome in patients with 
lung cancer.438 Up-regulation of S100A8 and S100A9 genes in bronchial airway 
epithelial cell brushings was found to be associated with smoking.439  
These results suggested that lack of S100A9 could decrease the accumulation of 
MDSC and thus open the opportunity to directly test the role of these cells in tumor 
progression.  In the urethane/CS model, it did not significantly reduce the number of 
initial tumor lesions but S100A9KO mice had much better survival than their wild-type 
   108 
counterparts. Recent study on the model of multiple myeloma has shown that improved 
survival of S100A9KO tumor-bearing mice was associated with improved tumor-specific 
response of CD8+T cells and was reversed by administration of MDSC.440  
Taken together, these data suggest that early stages of tumor development in 
CS related lung cancer are associated with accumulation of non-suppressive IMC. This 
further necessitates the search for a better way to therapeutically target these cells in 
cancer patients. IMC, for their part, may play an important role in tumor development via 
mechanisms not involving immune suppression. We recently have found that IMC could 
promote the development of skin cancer by recruiting pro-inflammatory CD4+ T cells 
(data not shown). These results indicate that IMC and MDSC may be a major factor in 
regulation various stages of tumor development and progression and their precise role 
needs to be further elucidated.    
   
Methods 
Mice.  All animal experiments were approved by University of South Florida 
IACUC. Mice were housed in pathogen-free facilities. FVB/N and C57BL/6 mice were 
obtained from National Cancer Institute (Frederick, MD). S100A9KO mice on C57BL/6 
background were described previously.194  
 
Lung carcinogenesis model.  Exposure of mice to CS was performed using a 
whole body smoke inhalation system (Teague TE-10C, Teague Enterprises, Davis, CA). 
Mice were exposed to an average of 250 mg/m3 total suspended particulate (TSP) of 
CS for 2 hours/day, 5 days/week during 2-4 months using the standard Federal Trade 
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Commission (FTC) method: a 2-second 35 cm3 puff once per minute for a total of nine 
puffs.  TSPs concentration was characterized daily by collecting particles on 25mm 
Pallflex membrane filters. Standard reference cigarettes 3R4F were purchased from the 
Tobacco Research Institute (university of Kentucky, Lexington, KY) and used in this 
study. At the end of week 3 of smoke exposure, some mice received single 
intraperitoneal (i.p.) injection of urethane (1.5 g/kg). CS continued for 3-4 more months. 
After 3 or 4 months of exposure to smoke, mice were euthanized and the presence of 
myeloid cells and the size and number of tumor lesions were evaluated. 
 
Preparation of single cell suspension and antibody staining. Lungs were 
thoroughly minced and digested in RPMI-1640 medium containing collagenase XI (2 
mg/ml; Sigma-Aldrich) at 37˚C for 15 minutes. Samples were resuspended in calcium 
and magnesium-free PBS-EDTA at room temperature. Red blood cell were lysed with 
ACK buffer, washed in PBS-EDTA, and passed through a 50 mm cell strainer. After 
single cell preparation cells were counted and stained with following Ab: Gr1-APC, 
CD11b-PEy7, F480-PE, CD11c-FITC   Ly6C-FITC and Ly6C-PE.  All antibodies were 
from BD bioscience.  
 
T cell suppressive activity of MDSC.  In experiments with CC10Tg mice on 
C57BL/6 background, the effect of MDSC on antigen non-specific (CD3/CD28 
antibodies inducible) and antigen-specific (OVA-derived peptide specific OT-1 CD8+ T 
cells) proliferation were measured. Briefly, T cells obtained either from wild-type 
C57BL/6 mice or from C57BL/6 OT-1 mice were labeled with CFSE and mixed with 
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irradiated (20Gy) syngeneic splenocytes at a 1:4 ratio. MDSC were added at different 
ratios and cells were stimulated with either 1 µg/ml CD3 and 0.5 µg/ml CD28 antibodies; 
or 0.5 µg/ml OT-1 specific peptide SIINFEKL. Proliferation of T cells was assessed 72 
hrs later by flow cytometry. Experiments were performed in triplicates. In experiments 
with urethane/CS models on FVB/N background, antigen-specific T cell proliferation 
was assessed using allogeneic mixed leukocyte reaction. Briefly, 105 splenocytes from 
BALB/c mice (responders) were mixed with 105 T cell depleted and irradiated (20Gy) 
splenocytes from FVB/N mice (stimulators) in U-bottom 96 well-plates. FACS purified 
Gr-1+ cells were added into wells at different ratios. On day 4, cells were pulsed with 3H-
thymidine (1 µCi/well; GE Healthcare) for 18 hrs. 3H-thymidine uptake was counted 
using a liquid scintillation counter and expressed as counts per minute (cpm). 
 
Evaluation of lung tumors.  Whole lungs were flushed with PBS and ﬁxed in 
4% paraformaldehyde for at least 24 hrs and parafﬁn embedded. Parafﬁn-embedded 
lungs were serially sectioned transversally at 4 µm and histologically examined with 
hematoxylin and eosin (H&E) stain.  
 
Evaluation of myeloid cells by flow cytometry.  Several populations of 
myeloid cells were evaluated in this study: 1) IMC/MDSC defined as Gr-1+CD11b+ cells, 
including subset of CD11b+Ly6CloLy6G+ granulocytic and CD11b+Ly6ChiLy6G- 
monocytic cells; 2) macrophages (MΦ), which were defined as Gr-1-CD11b+F4/80+ 
cells; and 3) DCs, defined as Gr-1-F4/80-CD11c+ cells. 
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Statistical analysis.  Statistical analysis was performed using unpaired 2-tailed 
Student t-test with significance determined at p<0.05. For the analysis of survival, Log-
Rank Mantel Cox analysis was used. 
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OVERALL CONCLUSION AND FUTURE THOUGHTS 
 
Participation of inflammation in the development of cancer has been established 
for many years. Dr. Rudolph Virchow first described the concept of “lymphoreticular 
infiltration” by observing particular cells invading in the emerging neoplastic tissues.7  
Later, many studies confirmed that the inflammatory environment, which includes 
different cellular and molecular components, plays a crucial role in the processes that 
leads to tumor formation.  Recapitulation of this idea brought back the interest to study 
the process of inflammation that induces cancer. 
Many studies in tumor development have implicated myeloid cell populations in 
the inflammation processes that lead to cancer development.11,179,441  In the past few 
years, many groups deciphered an immature myeloid population capable of 
suppressing the normal immune responses against neoplasm.150,442,443  It was 
demonstrated in this project, in two different models of inflammation, that the bone 
marrow derived immature myeloid cells population can also influence the tumor 
development. In the first model, upon inducing inflammation by tumor promoter, 
infiltrating IMCs were able to attract CD4 T helper cells by secreting CCL4 chemokines.  
This contributes to the concept that not only mature myeloid cells participates in the 
inflammatory environment but also immature cells within the myeloid population can 
reach the inflammation area at early stages and accelerate neoplastic development. In 
the first part of the project the overexpression of S100A9 in mice served as a preamble 
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of the inflammatory environment but additionally could contribute to the abundant 
infiltration of IMCs within the targeted site. S100A9 and its partner S100A8 have been 
linked not only with different types of cancer but also other health disorders such as 
cardiovascular, autoimmune and neurodegenerative diseases among others.164,186,189 In 
a cellular emphasis, this protein previously has been linked directly to accumulation of 
Gr1+ cells resulting from the deregulation of DC differentiation in established 
tumors.167,428 From this perspective, it was curious to investigate how its overexpression 
could influence, at the cellular level, the early stages of carcinogenesis. Most studies 
defined MDSCs as one of the principal collaborators in tumor onset and development.  
These particular immature cell populations, with Gr1 and CD11b surface markers, 
suppress directly the potent immune responses that are built against strange 
antigens.146,147 The presence of these cells has been well studied in established tumors 
and their environment characterized by inflammation.162 Recently, an interesting study 
revealed that MDSCs have increasing suppressive capacity which depends on the 
stage of the tumor. In this study the authors suggest that the suppressive capacity of 
these cells augments with the development of the tumor.444  Thus, the current study 
might provide a new perspective of how cellular components, within the early stages of 
carcinogenesis, can influence the inflammatory environment that leads to tumor 
formation. Naturally, trying to elucidate direct mechanisms of the cellular components in 
the tumor environment are the first approach of most studies but is now becoming 
equally interesting and important to study the indirect mechanisms of tumor 
development which can have a notorious impact in the development of new therapies.   
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The first part of this study showed that IMCs, with markers Gr1+ and CD11b+, 
indirectly contribute to tumorgenesis. Importantly, the implication of these cells in the 
inflammation process was sustained by the overexpression of S100A9 protein. It was 
found that these IMCs migrate from the BM and accumulate at the site of inflammation.  
Contrary to the immunosuppressive MDSCs found in established tumors, the Gr1+ 
CD11b+ cells found in the inflammation area don’t have suppressive capacity and were 
characterized with granulocytic phenotype.  Further, it was confirmed that the 
participation of adaptive immune cells in the inflammation environment increases the 
chances of tumor establishment. In most studies the presence of these cells has been 
linked with good prognosis but in recent years, studies confirmed that some CD4+ 
T helper cells phenotypes can contribute in suppressing immune protection and/ or 
inducing more inflammation.226,231,445 Indeed, in this project it is suggested that IMCs 
can bring CD4+ T helper cells to the inflammation environment and contribute to tumor 
development. It hasn’t been address, in this particular study, which of the known CD4+ 
T helper cells influence directly the tumor progression. From the recognized CD4+ T 
helper cells phenotypes is probably obvious to suggest that in the chronic environment 
we will going to find Th17 and/or Tregs regulating the inflammatory responses.  In the 
case of Th17, known to be a proinflammatory phenotype, can enhance the inflammatory 
environment by secreting IL-17 and IL-22.281,446 This idea might be an obvious 
suggestion since is also known that IMCs can secrete TGF-β and IL-6, the cytokines 
that are required for Th17 differentiation. In many cancerous tumors Th17s are found in 
high frequency compared to other T helper phenotypes.447,448 Sometimes these cells 
are the only contributors of IL-17 in the cancer environment which can signify a 
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detriment prognosis of a cancer patient.299 There is a very interesting study suggesting 
that human immature myeloid cells isolated from blood of cancer patients can influence 
the differentiation of uncommitted CD4 T cells into Th17 or T regulatory cells.305 
Although this phenomenon may explain the interaction of IMCs and CD4 T cells in the 
tumor microenvironment it requires detailed in vivo experiments to clarify how this might 
happens mechanistically. In this study, we provide a step forward that could contribute 
to explain how CD4 T cells and IMCs might interact in favor of tumor development.   
Alongside with the possibility of trying to elucidate which phenotype of CD4+ cells 
could participate during the early stages of carcinogenesis this study also suggest the 
participation of CD4 Tregs, the cells that are characterized by their suppressive 
activity.309  CD4 Tregs are found often when the tumors are already established and 
present one of the mechanisms of tumor escape.449,450 Tregs might participate in 
carcinogenesis by secreting pro-inflammatory cytokines.  Several studies suggest that 
FoxP3-expressing CD4 Tregs secretes IL-17 cytokine in the inflammatory 
environment.451,452 This behavior is explained by the plasticity of Th17 and Tregs. 
Several studies described this phenomenon in pre-neoplastic inflammatory 
environment.301,305 So it will be interesting to investigate the mechanisms by which the 
inflammation process, at early stages of tumor formation, can induce the phenotype 
switch of CD4 T cells and what would be the consequences of this phenomenon in the 
specific environment. It will be very useful to try to clarify if the CD4 T cells that are 
infiltrated in the inflammation environment are contributing directly as IL-17-secreting 
CD4 T cells or if these CD4 T cells are the regulatory phenotype that suppresses the 
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early responses of the adaptive immune system which allow the aggressive 
development of inflammation and tumor formation.   
Another interesting point that was elucidated in this study is that the infiltration of 
CD4 T cells was driven by the expression of CCL4 chemokine by IMCs. To our, 
knowledge this is the first time that is reported that CCL4 chemokine is secreted by non-
suppressive IMCs and recruits CD4 T cells during the inflammation that leads to tumor 
formation. This deciphered event not only can lead to develop a different strategy for 
early diagnosis of cancer but also unveiled a possible new pathway of tumor formation.  
In cancer related studies chemokines are mostly secreted by stroma cells, tumor cells 
and/or mature myeloid cells to attract other inflammatory cells that support cancer 
development. They together orchestrate a complex scheme to alter the immune system 
to benefit or obstruct the inflammation environment.  Thus, chemokines may serve as 
the link between both immune systems that together can promote the establishment of 
tumors.   
Continuing with the same phenomenon, in the second part of this project it was 
addressed the effect of the inflammation caused by cigarette smoke in mice.  Although 
is well known that cigarette smoke can serve as tumor initiator agent we wanted to find 
out if MDSCs could participate in this process.  It was shown, in the second part of this 
study, that there is a significant accumulation of Gr1+ CD11b+ cells in the blood of mice 
exposed to cigarette smoke during the first three months of treatment.  Interestingly, 
when we analyze the function activity of these cells we found that these cells are not 
suppressive. Surprisingly, these results were similar to the results found in the 
inflammation skin experiments, confirming that these IMCs that accumulate in the 
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previous events of carcinogenesis might contribute to tumor formation by non-
suppressive mechanisms. In the smoking project we had the opportunity to analyze 
Gr1+ CD11b+ cells that accumulate in different organs upon carcinogen and smoking 
treatment. We found that these cells were suppressive only if tumors were present 
suggesting that there could be a mechanism that converts non-suppressive 
Gr1+CD11b+ cell into suppressive MDSCs during the early events of tumor formation. It 
will be interesting to analyze the mechanisms that are responsible for the ability of these 
cells to reach the suppressive state and facilitate the process of tumor formation. 
Condamine et al. proposed in a review a “two-signal” stage that these specific IMCs 
possibly undergo to accumulate and acquire suppressive characteristics. In this review 
he described that the “first signal” is influenced mainly by colony stimulating factors 
(CSFs), such as GM-CSF, G-SCF and M-CSF, which promote the accumulation of 
these IMCs. To acquire the functional characteristic they could require a “second 
signal”. During this following stage pro-inflammatory factors, such as IL-6, IL-1β, IFN-γ, 
could promote the upregulation of suppressive enzymes and cytokines which contribute 
to the altered immune system.165  This “two-signal” concept could explain the cellular 
involvement in this model of chronic inflammation since CSFs and proinflammatory 
molecules are overly secreted within this environment and attract IMCs expressing the 
corresponding receptors. This suggestion could explain partially how IMCs are recruited 
into the inflammation site however, it still remain unclear why these cells could not 
become suppressive even though that are located in a constant pro-inflammatory 
environment to do so.  Although at a molecule level the inflammation environment is 
well studied perhaps there is a specific scenario where the cells become insensitive and 
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when the tumor appears the environment changes and induces the functional 
immunosuppressive capacity into these cells. More complex investigations are required 
to clarify why these cells remain in a non-suppressive state and why are still important 
for tumor formation.  
We further found out that the absence of S100A9 protein in mice improved 
survival of the carcinogen/smoked group compared to its WT counterparts. Recent 
studies showed that the presence of this protein is correlated with the infiltration of 
myeloid cells and poor prognosis in cancer patients.163,397,437  Our lab established a 
direct link in the overexpression S100A9 protein and the accumulation of MDSCs in the 
tumor environment.167 So we were interested to know if MDSCs have a role in the 
establishment and progression of the tumor. We showed that in the absence of S100A9 
protein there were less accumulation of Gr1+ CD11b+ cells in the lung and spleen 
compared to WT mice after carcinogen/smoking treatment. This particular result is 
somehow expected because it is known that the cells with these surface markers 
accumulate in established cancer. Further, and more importantly, we confirmed that 
cells isolated from the spleen and lung of WT mice are more suppressive than 
S100A9KO mice.  
In this smoking project we were able to distinguish the stages of tumor formation 
by analyzing the function of IMCs within the lung and spleen. We confirmed that during 
inflammation Gr1+ CD11b+ cells accumulate in the lung of smoked mice that could 
favor the eventual development of cancer. These cells, in this particular environment, 
are not suppressive but they must contribute somehow in the establishment of a chronic 
inflammation that leads to cancer. These results open the possibility to improve 
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therapeutic approach by targeting different stages of carcinogenesis. Similarly to the 
first part of this project, we utilized S100A9 KO mice to address the contribution of IMCs 
in the survival of the smoked mice. We showed that the absence of this protein 
improved the resistance to the inflammation caused by the smoking exposure.  Since 
CS treatment alone wasn’t capable to induce tumor appearance we introduce the lung 
carcinogen urethane to study the suppressive capacity of Gr1+ CD11b+ cells found 
within the tumor. As expected the IMCs isolated from the lungs with tumor lesions were 
suppressive which fits the MDCS functional characteristic.  
To recapitulate the whole project we could say that we identified the 
characteristics of IMCs at different stages of inflammation-related cancer development 
by employing two different inflammation models.  These two models have in common 
the inflammation-induce tumor development concept but are designed differently, which 
allow confirming the results.  With the first model, the skin project, we elucidate from the 
inflammation stages which immune cells and what possible mechanism they utilized to 
promote carcinogenesis. With the smoking project we utilized a different concept of 
inflammation and consistently with the skin project showed that the IMCs present in the 
inflammatory environment aren’t suppressive. In the skin study we found that these 
IMCs draw CD4 T cells with chemokines to the inflammatory environment to promote 
tumor development but we didn’t study the actual tumor stages. Moreover, in the 
smoking project we took a step forward in the stages of carcinogenesis and confirmed 
with previous studies that the IMCs present in the tumor microenvironment itself are 
MDSCs. In the smoking study the type of T cells involved in tumor development was not 
addressed. However, since in both studies the non-suppressive IMCs are present it 
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would be natural to speculate that CD4 T cells could participate. It is necessary, and 
very interesting, to perform further experiments to decipher which of the CD4 T cell 
phenotype could participate in the inflammation process that leads to tumor 
development in both models. This information not only will contribute to the biology of 
cancer development but also could help develop new therapeutic approaches that can 
intervene in the early stages of tumor formation characterized by inflammation.  
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